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Primaquine is an important antimalarial drug that is often dose-limited in therapy by 
the onset of hemolytic anemia. It is well accepted that this toxicity is due to the action of 
its metabolites and not the parent compound. However, the toxic species have not been 
identified and little is known about the mechanism underlying primaquine-induced red 
cell injury. Previous studies to identify the hemotoxic metabolites have focused on the 
redox active phenolic derivatives of primaquine and have shown that a number of these 
compounds are capable of decreasing red cell aSH levels and oxidizing oxyhemoglobin 
to methemoglobin. However, these derivatives have not been detected in humans 
following primaquine administration. Since N-hydroxy metabolites are known to mediate 
the hemotoxicity of several other ary lamines, this dissertation addresses the possibility 
that an N .. hydroxy metabolite of primaquine may playa role in the hemotoxicity of the 
parent compound. 
Metabolic studies in rat and human microsomes determined that the known human 
primaquine metabolite, 6-methoxy-8-aminoquinoline (6-MAQ) is N-hydroxylated to 6-
methoxy .. 8 .. hydroxylaminoquinoline (MAQ-NOH). MAQ-NOH was shown to be 
hemolytic in vivo in rats, and directly hemotoxic in rat erythrocytes. These observations 
suggest that primaquine can be metabolized to MAQ-NOH and that this metabolite has 
the requisite properties to playa role in the hemotoxicity of the parent compound. 
In regard to the mechanism underlying MAQ-NOH hemolytic activity, it was 
demonstrated that under hemolytic conditions, MAQ-NOH induced an oxidative stress 
within red cells, but the pattern of responses was quite different than other N-
hydroxylamines previously shown to have direct hemolytic activity. 
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In this dissertation, data is presented to suggest that MAQ-NOH may induce 
hemolytic injury in the red cell by more than one mechanism; one that involves lipid 
peroxidation in the presence of normal amounts of erythrocytic GSH, and one that 
involves protein oxidation in red cells with low levels of GSH, as seen in individuals with 
glucose-6-phosphate dehydrogenase deficiency. The relative contribution of MAQ-NOH 




Drug-Induced Hemolytic Anemia 
Hemolytic anemia occurs when red blood cells are removed prematurely from the 
circulation and the bone marrow is unable to compensate for the loss. It has been a well-
recognized toxic side effect of drugs for many years with the first case reports on the 
capacity of phenacetin to induce anemia documented in the 1890's (Cleaves, 1892; West, 
1893). While initially the problem of drug-induced hemolytic anemia was given little 
attention, it became of great social and military concern during World War II and the 
Korean War in response to a high incidence of hemolytic anemia in otherwise healthy 
military personnel prophylactically administered primaquine for malaria (Beutler, 1959). 
In addition to primaquine, many other compounds are known to induce a hemolytic 
response (Beutler, 1959). These include a wide range of structurally and functionally 
diverse compounds (Table 1.1) such as the aryl amine drug dapsone, the antibacterial 
agent chloramphenicol, and the herbicide propanil. While there does not appear to be any 
link in their pharmacological activity that predisposes these compounds to be hemolytic 
agents, many of them contain an arylamine nucleus (fig 1.1) or can be metabolically 
converted to an aromatic amine in vivo. 
Glucose-6-Phosphate Dehydrogenase Deficiency 
It was early recognized that hemolytic anemia in response to primaquine was most 
pronounced in a particular sub-population of individuals. These include 10-15% of 
African Americans (A-) and some Caucasians of Mediterranean descent (Med-), the 
Table 1.1 
Compounds Known to Induce Hemolytic Anemia 
Analgesics 
Acetanilid 




Sulfonamides and Sulfones . 



























(*) Slightly hemolytic in African Americans, or only in very large doses 
(**) Hemolytic in Caucasians, but not in African Americans 
(***) Possibly hemolytic in Caucasians, but not in African Americans or Orientals 
















percentage depending on geographical location (Beutler, 1972). This sensitivity was later 
associated with an intrinsic genetic defect in the enzyme glucose-6-phophate 
dehydrogenase (G6PD). G6PD deficiency is an X-linked recessive trait that affects up to 
400 million people worldwide (for review see Beutler, 1990). While it is recognized that 
multiple variants of this enzyme deficiency exist, a majority of them result from a single 
point mutation that causes an amino acid change in the protein. It is thought that these 
mutations occur within the dimer interface of the protein, destabilizing the dimer, and 
exposing the monomeric forms to enhanced degradation (Mason, 1996). Thus, the 
mutated enzyme has a normal level of activity but a shorter cellular lifespan. Due to the 
lack of protein turnover in red cells, G6PD activity is lost as the erythrocyte ages. 
Erythrocytes are considered depleted of the enzyme activity after 55 days and 20 days in 
A- and Mediterranean varj.ants, respectively. 
G6PD is the first enzyme in the hexose monophosphate shunt metabolic pathway and 
is solely responsible for generating NADPH in erythrocytes. NADPH is an essential 
cofactor for the antioxidant enzyme catalase and the glutathione peroxidase/ reductase 
enzyme system (Kirkman and Gaetani, 1984). Therefore, while G6PD-deficient 
individuals may not experience any pathology under normal conditions, they are unable 





In recent literature, malaria was recognized as one of the world's most devastating 
human infectious diseases responsible for an estimated 1.5-2.7 million deaths each year, 
most of which are children under the age of five (Phillips and Phillips-Howard, 1996; 
Miller, 1997). Furthermore, another 300-500 million people are reported to be infected 
with the parasite each year and an additional 2.4 billion people are potentially exposed to 
the parasite on a daily basis (Phillips and Phillips-Howard, 1996; Miller, 1997). Although 
a majority of malaria cases occur in sub-Saharan Africa, it is believed that more than 100 
countries throughout Southeast Asia, the Indian subcontinent, the South Pacific region 
and Latin America are burdened with this problem (Kondrachine and Trigg, 1997). In 
addition, over 1000 cases of malaria per year have been reported in the last decade to the 
US Centers for Disease Control; most of these are due to international travelers returning 
from endemic areas (Kondrachine and Trigg, 1997; Magill, 1998). 
Parasite Life Cycle 
Human malarial infections are caused by four species of the plasmodial parasite, 
Plasmodiumjalciparum, P. vivax, P. ovale, and P. malariae (Tracy and Webster, 1996). 
Individuals primarily contract malaria following a bite from an infected female 
Anopheles mosquito. While feeding, the mosquito releases sporozoites from their salivary 
glands into the bloodstream of an individual. Once in the bloodstream, the sporozoites are 
quickly taken up by the liver and begin the prim~y tissue phase of infection. During this 
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phase, the sporozoites multiply and develop within hepatocytes into mature tissue 
schizonts. After 5-16 days, depending on the species, the schizonts rupture and release 
thousands of merozoites into the circulation where they invade red blood cells, initiating 
the erythrocytic or blood stage of malaria. Of importance, upon release from the liver, the 
parasite is unable to re-infect other tissues. However, in P. vivax and P. ovale infections, 
some of the parasites remain in the Ii ver, gi ving rise to the latent tissue form of the 
parasite. This form of the parasite is released into the bloodstream at a later date, thus 
. causing relapses. Once in the red cell, most of the plasmodia continue to multiply and 
develop into schizonts until the red cell ruptures, again releasing merozoites that can 
further infect additional erythrocytes. However, some of the parasites will differentiate 
sexually within the red cells into gametocytes. It is this form of the parasite that is 
ingested by an uninfected mosquito and ultimately develops within the mosquito into a 
sporozoite that can infect another individual following the infected mosquito's next blood 
meal. 
Therapy 
The antimalarial drugs in use today are active against different stages of the malaria 
parasite (Tracy and Webster, 1996). However, a majority of them are used clinically to 
target either the erythrocytic or the tissue forms of the species. For example, both 
chloroquine and quinine are known to have gametocidal activity but are primarily used to 
kill the asexual blood forms of the parasite. Additional agents active against the blood 
forms of malaria include mefloquine and halofantrine. Primaquine is an antimalarial drug 
of particular value in that it has been shown to be active against multiple stages of the 
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parasite. These include the erythrocytic stages of P. vivax, the primary hepatic forms of 
P. jalciparum, and the gametocidal form of all four malaria species (Grewal, 1981; 
Peters, 1999). In addition, primaquine is known to be highly effective in treating the 
persistent exoerythrocytic, or tissue, form of malaria and therefore is particularly 
important clinically for the radical cure of P. vivax and P. ovale infections. 
Drug Resistance 
The widespread emergence of drug resistant parasites has been the subject of several 
recent reviews (Kondrachine and Trigg, 1997; Foley and Tilley, 1998; Milhous and Kyle, 
1998). The alarming resurgence s~en in malaria cases is thought to be largely due to this 
problem. For example, chloroquine resistance has been documented in almost all malaria 
endemic areas except Central America (Kondrachine and Trigg, 1997). As this was once 
the drug of choice for malaria, its clinical effectiveness has been drastically reduced in 
the last 20 years. Furthermore, resistance to the altemati ve sulfadoxine-pyrimethamine is 
now rampant in Africa, Southeast Asia and South America (Kondrachine and Trigg, 
1997; Milhous and Kyle, 1998). As an alternative course of treatment, infected 
individuals are being administered the more expensive antimalarial agents such as 
mefioquine, quinine and halofantrine, however, an alarming number of cases of 




In response to a shortage of the antimalarial agent quinine during World War II, the 
US initiated a large research program to develop more effective, safer antimalarial drugs 
(Greenwood, 1995). From this program, emerged the 8-aminoquinoline, primaquine, 
synthesized by Robert Elderfield (Elderfield et aI., 1955). Extensive use in American 
soldiers suffering from relapsing vivax malaria during the Korean War (Garrison et aI., 
1952; Alving et aI., 1953) helped to establish the clinical value of primaquine as the drug 
of choice for the radical cure of malaria. 
Primaquine continues to be the only drug used clinically today to eliminate the latent 
tissue forms of P. vivax and P. ovale infections. Moreover, recently the gametocytocidal 
activity of primaquine has been exploited in its co-administration with blood 
schizontocidal drugs like chloroquine in an effort to combat the widespread drug 
resistance to these agents particularly in P. falciparum infections, the most deadly species 
of malaria in humans. (Baird et aI., 1995; Peters, 1999). Of interest, the clinical use of 
primaquine has also recently expanded to include treatment of Pneumocystis carinii 
pneumonia in patients with acquired immunodeficiency syndrome (Black et aI., 1991; 
Toma, 1991; Kantor, 1992). 
Mode of Action 
Despite its use for more than forty-five years, the therapeutic mode of action of 
primaquine is unknown. In particular, it is not understood why primaquine is more 
effective against ~he hepatic stage, than it is against the asexual blood stages of the 
10 
parasite. Furthermore, the questio~ remains as to whether primaquine anti m.alari al 
activity is due to the parent compound or its metaboli tes. One problem facing 
investigators in trying to elucidate this mechanism is the lack of a well-developed in vitro 
culture system for the latent tissue stages of P. vivax and P. ovale. 
While attempts to develop an in vitro culture systems for the human malaria species 
have not been successful, two rodent forms, P. yoelii and P. berghei, have been cultured, 
in vitro. In this regard, Bates et. al. (Bates et aI., 1990) synthesized a variety of 
primaquine analogs and in comparison studies using P. berghei infected HepG2 cells 
determined that certain primaquine derivatives were much more potent antimalaria.l 
agents than primaquine. These investigators further demonstrated that these derivatives 
displayed a linear correlation between spontaneous superoxide formation and antimalarial 
activity suggesting that primaquine is converted in the liver to redox active intermediates 
that contribute to the parent compound antimalarial activity by inducing an oxidative 
stress within the parasite. These data are consistent with previous studies in which redox 
active compounds like alloxan, phenylhydrazine, and divicine were shown to sl:lppress 
parasitaemia in malaria-infected mice (Clark and Hunt, 1983; Clark et aI., 1984b; Clark et 
aI., 1984c). 
In contrast, a second group of investigators have proposed that primaquine itself 
exerts its antimalarial activity by binding the Plasmodium ubiquinone binding site on 
cytochrome b, thereby interrupting the parasite's mitochondrial respiratory chain (Vaidya 
et aI., 1993). Specificity has been attributed to the unique structural features of the 
parasite ubiquinone-binding site. In support, when tested in vivo in rats infected with P. 
yoelii, primaquine induced thickening of the parasite mitochondrial membranes as well as 
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dramatic mitochondrial swelling (Boulard et aI., 1983; Bates et aI., 1990) with no effect 
on host hepatocyte mitochondria. Although not a hypnozonticidal antimalarial agent, 
atovaquinone is known to mediate its activity via this mechanism (Fry and Pudney, 1992; 
Srivastava et aI., 1997). 
Resistance 
There have recently been some reports in the literature of P. vivax resistance to 
primaquine treatment in Papua New Guinea, Southeast Asia, and Central and South 
America (Krotoski, 1980; Arias and Corredor, 1989; Luzzi et aI., 1992; Bunnag et aI., 
1994; Gascon et aI., 1994; Nayar et aI., 1997). In support of these observations, resistance 
has been induced experimentally to the blood schizontocidal activity of primaquine in a 
number of malaria species including P. vivax in humans (Arnold et aI., 1961; Thompson, 
1967). However, as pointed out by Collins et. ai., (Collins and Jeffery, 1996) these cases 
are often in endemic areas that are infested with particularly virulent strains of P. vivax 
(Le., Chesson strain from New Guinea) that are known to require higher doses of 
primaquine to be eradicated, which suggest that these are cases of tolerance not 
resistance. In addition, subsequent examination of many of these reports has determined 
that sub-therapeutic dosing, lack of compliance, and re-infection may also contribute to 
what appeared to be relapses (Collins and Jeffery, 1996; Looareesuwan et aI., 1997). 
As a result of the widespread parasite resistance to many of the blood schizontocides 
and possibly to primaquine, it is imperative that new antimalarial agents be developed. 
To do so, researchers need to understand the mechanism of action, toxicity, and parasite 
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resistance to the existing drugs in order to rationally design more effective drugs with a 
higher therapeutic index. 
Primaquine Hemotoxicity 
Primaquine therapeutic and prophylactic use is limited by its toxic side effects, 
methemoglobinemia and hemolytic anemia (Tarlov et aI., 1962; Carson et aI., 1981; 
Clyde, 1981). Early clinical studies in G6PD A- deficient individuals characterized the 
course of the hemolytic response into three phases: acute, recovery, and resistant phases 
(Dern et aI., 1954). During the acute hemolytic phase, up to 50% of the red cells may be 
lost from the circulation. A decrease in blood GSH levels, a transient increase in: 
methemoglobin levels and the appearance of intraerythrocytic inclusions (Heinz bodies) 
have been reported to acc<;lmpany this phase. 
Despite continuing primaquine therapy, these patients begin to recover in 7-12 days 
following administration of the drug. Beutler and others (Kellermeyer et aI., 1961; 
Beutler, 1971) have shown that this self-limiting hemolytic response in A- individuals is 
due to the selective destruction of older erythrocytes with decreased G6PD enzyme 
activity. As the red cell population becomes enriched in younger cells, the patient 
becomes "resistant" to the hemolytic response. Although the surviving cells become 
sensitive to primaquine as they age and are removed from circulation, their loss is 
compensated for by erythropoiesis. If drug treatment is discontinued, however, fun 
susceptibility returns within 4-6 months as the red cells return to the normal pre-drug age 
distribution. 
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In contrast, the hemolytic response in the Mediterranean variant of G6PD deficiency 
is not self-limiting (George et aI., 1967). In Med- individuals the G6PD activity is 
markedly decreased in both young and old cells (Piomelli et aI., 1968). Thus a hemolytic 
response in these individuals may be much more severe than in an A- variant, perhaps 
even life-threatening. 
Primaquine Metabolism 
It is interesting that despite the importance of metabolism in regard to the mode of 
action and toxicity of primaquine (Tarlov et aI., 1962; Fraser and Vesell, 1968; Fletcher 
et aI., 1988; Bates et aI., 1990), its metabolic fate remains poorly defined. The chemical 
instability of the putative primaquine metabolites, along with their poor recovery from 
biological systems has significantly contributed to the difficulty of this problem.(Strother 
et aI., 1984; Idowu et aI., 1995). Pharmacokinetic studies of primaquine in humans have 
determined that drug bioavailability is 96%, half-life is 6 hours, and volume of 
distribution is 250 L indicating extensive uptake into the tissues (Mihaly et aI., 1984; 
Mihaly et aI., 1985). Therefore since primaquine is taken chronically (or sub-chronically) 
for malaria, the potential exists for drug and/or metabolite accumulation in vivo. 
Furthermore, less than 2% of t~e administered dose of primaquine is renally excreted 
(Mihaly et aI., 1984). 
The primary metabolic pathways of primaquine (fig. 1.2) are thought to involve 
oxidative metabolism of both the aminoquinoline ring and the alkylamino side-chain of 
the molecule (Strother et aI., 1981; Price and Fletcher, 1986; Idowu et aI., 1995). 
Primaquine-3' -carboxylic acid (PQ-CX) has been found in the plasma of humans (Mihaly 
JvvH, fro- JvvH, 
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Fig. 1.2. Putative pathways of primaquine metabolism. PQ-NOH, N-hydroxyprimaquine; 
PQ-CX, 8-(3-carboxy-1methylpropylamino)-6-methoxyquinoline; MAQ-NOH, 6-
methoxy-8-hydroxylaminoquinoline; 6-DesM-PQ, 6-desmethylprimaquine; 5-0H-PQ, 5-
hydroxyprimaquine; 6-MAQ, 6-methoxy-8-aminoquinoline; 5-0H-6-MEOAQ, 5-
hydroxy-6-methoxy-8-aminoquinolone; 5,6-DHAQ, 5,6-dihydroxy-8-aminoquinoline; 
5,6-
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et aI., 1984) and rats (Baker et aI., 1982; Clark et aI., 1984a) in significantly higher 
concentrations than the parent compound, however, this metabolite was not detected in 
the urine, indicating further metabolism prior to excretion. The only other known human 
metabolite of primaquine is the N-dealkylated derivative, 6-methoxy-8-aminoquinoline 
(6MAQ), which was found in the blood and urine of primaquine treated volunteers (Baty 
et aI., 1975). 
Two phenolic metabolites, 5-hydroxyprimaquine (5-0H-PQ) and 6-
desmethylprimaquine (6-DesM-PQ) have been identified in the urine of primaquine 
treated dogs (Strother et al., 1981). In addition to these, 5,6-dihydroxyprimaquine 
(5,6DHPQ) was detected in the bile of rats during isolated rat Ii ver perfusion studies 
(Ward et aI., 1985). In rat liver microsomal studies, using an ethylchloroformate 
derivatization technique, Idowu et. al. (Idowu et aI., 1995) identified multiple metabolites 
of primaquine including side chain and phenolic oxidation products. However, these 
investigators did not detect the major rat primaquine metabolite PQ-CX. Conversely, PQ-
ex was the only metabolite detected in human liver microsomes (Bangchang et aI., 
1992). 
Oxidative Stress in the Red Blood Cell 
The ability of hemoglobin to reversibly bind molecular oxygen and carbon dioxide is 
essential for tissue oxygenation and removal of carbon dioxide. When bound to 
hemoglobin, oxygen is known to e'xist in an equilibrium mixture (fig. 1.3) between 
oxyhemoglobin and a superoxide-ferri hemoglobin complex (Wittenberg et aI., 1970). 




Oe3+-D2- 0 3+ • ~ ... + 02-
MetHb Superoxide 
MetHb Reductase I SOD 
NADH 
Fe2+ 




Fig. 1.3. Normal production of active oxygen species within the red cell as a consequence 
of ferric iron-superoxide anion dissociation from oxyhemoglobin. Hb = oxyhemoglobin; 
MetHb = methemoglobin; SOD = superoxide dismutase; GPXlGR = glutathione 
peroxidase/ glutathione reductase. 
(from JoBow, 2001) 
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one of the four unpaired electrons in the outer (d) shell of the heme ferrous iron. When 
oxygen is released from hemoglobin, this electron is usually returned to the heme iron. 
However, if the electro,n remains With the oxygen during its release from hemoglobin, the 
result is the formation of methemoglobin and a superoxide anion radical (Mansouri and 
Lurie, 1993). Dissociation of the superoxide-ferri hemoglobin complex occurs constantly 
in normal red blood cells, and results in the conversion of up to 0.5% of total body 
hemoglobin to methemoglobin per hour (Chiu et aI., 1985). 
The red cell contains a number of enzyme systems to cope with the consequences of 
this oxidative reaction. Thus methemoglobin is readily reduced back to hemoglobin by a 
NADH-dependant redu<;tase (Passon and Hultquist, 1972), and the superoxide is 
converted to hydrogen peroxide by superoxide dismutase (Fridovich, 1975). The 
hydrogen peroxide, in turn, is detoxified by two enzyme systems, catalase and 
glutathione peroxidase/glutathione reductase (Eaton, 1991) as follows: 
GSH Red 
GSSG .. 2GSH 
Both catalase and glutathione peroxidase/glutathione reductase enzyme systems 
require NADPH (Kirkman and Gaetani, 1984). The sole source of this cofactor in the red 
cell is the first two steps of the hexose monophosphate shunt pathway, the activity of 
which is controlled by a feedback inhibition of the first enzyme in the sequence, G6PD 
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by NADPH. Under normal conditions, red cell G6PD is believed to function at less than 
3-5% of its maximum capacity (Yoshida and Lin, 1973) and hence the red cell has a 
significant reserve capacity to enhance production of this protective reduc~ant in the face 
of increase in oxidative stress. 
That this constant low-level oxidant stress has physiological consequences is well 
illustrated by the fact that human red cells that are deficient in G6PD activity have 
significantly lower levels of GSH and much shorter life spans (Gaetani et aI., 1979). For 
example, the red cells of individuals with the A- type of G6PD deficiency experience a 
20% reduction in red cell life span (Harris and Kellermeyer, 1972) . 
It has also long been known that a variety of drugs and other environmental chemicals 
can enhance the normal level of oxidant stress within the red cell, as indicated by 
increased cellular levels of methemoglobin and hydrogen peroxide. Chemicals well 
characterized to have this effect include phenylhydrazine (Cohen and Hochstein, 1964; 
Goldberg et aI., 1976), menadione (Cohen and Hochstein, 1964; Goldberg et aI., 1976), 
and phenylhydroxylamine (Kiese, 1974). More recently, additional active oxygen and 
other reactive species have been recognized to be formed under these pro-oxidant 
conditions. Thus superoxide, hydroxyl radical, glutathione and hemoglobin thiyl radicals 
and ferrylheme have all been detected in red cells exposed to arylhydroxylarnines such as 
phenylhydroxylamine and dapsone hydroxylamine (Maples et aI., 1990; Bradshaw et aI., 
1995; Bradshaw et aI., 1997). 
Since compounds that enhance oxidant stress within the red cell are hemolytic, and 
since red cells that are deficient in their capacity to produce the protective reductant, 
NADPH when faced with such an oxidant stress (i.e., G6PD deficient cells), are uniquely 
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sensitive to these hemolytic agents, it has long been considered that the hemotoxicity 
results from damage to the cell inflicted by these oxidant species. However, precisely 
how these reactive species arise and which of them are responsible for the injury, as, well 
as the identity of the cellular targets, are still unknown and are the subject of much 
ongoing research. 
While it is well recognized the superoxide itself is a relatively non-reactive species. in 
biological systems (Sawyer and Valentine, 1981), in the presence of hydrogen peroxide, 
this radical can lead to the formation of the highly reactive hydroxyl radical via an iron-
catalyzed Fenton reaction (McCord and Day, 1978; Halliwell and Gutteridge, 1992). The 
hydroxyl radical could further react with cellular sulfhydryl groups to generate thiyl 
radicals (Maples et aI., 1990; Bradshaw et aI., 1991; Bradshaw et aI., 1995), any of which 
are capable of inducing oxi~ative damage to cellular macromolecules, ultimately marking 
the red cell for premature removal from the circulation by macrophages of the spleen. 
One problem with this scheme is that ferrous iron is required to catalyze the Fenton 
reaction, and the ability of hemoglobin to catalyze this reaction is controversial 
(Gutteridge, 1986; Puppo and Halliwell, 1988; Dong Mao et aI., 1994). However, 
Comporti and colleges have shown that oxidation of hemoglobin to methemoglobin in 
red cells treated with hemolytic agents such as phenylhydrazine (Ciccoli et aI., 1994), 
divicine (Ferrali et aI., 1992), phenylhydroxylamine, and dapsone hydroxylamine' 
(Ciccoli et aI., 1999) resulted in the release of diffusible "redox-active" iron. 
In addition to hydroxyl radical generation, hydrogen peroxide is also known to react 
with hemoglobin to form the doubly oxidized hemoglobin species, ferrylhemoglobin 
(Kanner and Harel, 1985b; Kanner and Harel, 1985a; Harel and Kanner, 1988). 
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Perrylhemoglobin (Hb-Fe4+-OH) is a potent oxidant which has been shown to be capable 
of initiating red cell membrane lipid peroxidation (Kanner and Harel, 1985b; Kanner and 
Harel, 1985a; Galaris et ai., 1990). In addition, ferrylhemoglobin may also react with 
oxyhemoglobin in a comproportionation reaction to form methemoglobin (Giulivi and 
Davies, 1990). 
HbFe 4+_ OH + HbFe 2+_ 02 -~ .. 2HbFe 3+ + 02 
In brief, red cells are well known to be subject to an auto-oxidation that results in the 
formation of methemoglobin and hydrogen peroxide. The red cell is well equipped with 
oxidant defenses that re-reduce the methemoglobin and detoxify the peroxide. The 
hemolytic activity of a variety of arylhydroxylamines and other chemicals has been 
associated with an enhancement of this normally low level oxidant stress and is presumed 
to result from production of oxidant species at levels andlor rates above the red cells 
capacity to remove them. At levels above the protective threshold, additional and more 
toxic oxidant species are thought to arise and it is these species which are considered to 
be responsible for the cellular injury that causes shortening of the red cell life span by 
inducing premature splenic sequestration. 
Mechanism of Hemotoxicity 
While the mechanism by which hemolytic agents damage red blood cells to the extent 
they are removed prematurely from circulation is poorly understood, it is believed that 
these agents enhance the process of normal reactive oxygen species formation such that 
the antioxidant defenses in the red cell are overwhelmed resulting in an "oxidative stress" 
(Beutler, 1959; Tarlov et aI., 1962; Miller and Smith, 1970; Gordon-Smith and White, 
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1974; Carrell et aI., 1975). Observations that support this idea include: 1) a decrease in 
reduced red blood cell glutathione accompanies a hemolytic episode, 2) hemoglobin 
oxidation to methemoglobin and the formation of Heinz bodies (denatured hemoglobin) 
following exposure to hemolytic agents, and 3) an enhanced sensitivity to these drugs in 
individuals that have a decreased ability to generate adequate levels of NADPH (i.e~, 
G6PD-deficient people) when presented with an oxidative challenge. It was also realized 
during these early mechanistic studies that many of these hemolytic agents were not 
strong oxidizing or reducing agents and did not induce hemolytic damage when incubated 
with red cells in vitro at physiological relevant concentrations (Fraser and Vesell, 1968; 
Miller and Smith, 1970; Fletcher et aI., 1988). Thus the concept developed that many of 
these hemolytic compounds were metabolized in vivo to more redox active species. that 
were responsible for oxidizing critical cellular constituents and initiating the premature 
removal of the red cells from circulation (Tarlov et aI., 1962; Fraser and Vesell, 1968; 
Beutler, 1971). 
In this regard, investigators have examined the possible role primaquine phenolic 
derivatives may play in the parent compound toxicity. 5-0H-PQ, 5,6-DHPQ, and 5,6-
DHAQ, have been shown in vitro to deplete erythrocytic GSH and oxidize 
oxyhemoglobin to methemoglobin in both normal and G6PD deficient,red cells (Fraser 
and Vesell, 1968; Agarwal et aI., 1988; Fletcher et aI., 1988). It is proposed that these 
compounds playa role in primaquine-induced hemotoxicity by redox cycling within the 
red cells to their corresponding quinone/ quinone-imine derivatives consequently forming 
reactive oxygen species that oxidize critical cellular constituents terminally damaging the 
cell (Vasquez-Vivar and Augusto, 1992; Vasquez-Vivar and Augusto, 1994). It is of 
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interest that phenolic metabolites of the hemolytic agent aniline were also found to 
oxidize hemoglobin in vitro, however, they were not hemolytic in vivo in rats (Harrison 
and Jollow, 1986; Harrison and Jollow, 1987). These metabolites although formed in the 
liver, are quickly cleared by conjugation reactions and therefore do not contribute to the 
parent compound toxicity. 
Although it is widely accepted that drug-induced hemolytic anemia results from 
oxidati ve damage to the red cells, the mechanism in which these agents impose this 
damage is not known. However, some evidence is available to suggest that more than one 
mechanism may exist. An elegant study conducted in 1966 on inmates in the Illinois 
State Penitentiary (Degowin et al., 1966), illustrated in figure 1.4, demonstrated that 
when the hemolytic drug dapsone was administered to G6PD-normal and G6PD-deficient 
(A-) volunteers, there was moderate induction of hemolytic anemia in normal individuals 
and about a 2-fold increase in sensitivity towards dapsone-induced hemolytic anemia in 
G6PD-deficient individuals. In marked contrast, primaquine had little hemolytic activity 
in normal individuals, however, A- G6PD deficiency was associated with a 30-fold 
increase in sensitivity to primaquine hemotoxicity. While interpretation of the data 
remains unclear, it argues strongly for marked variations in the response of red cells to 
hemolytic metabolites of these two drugs. 
Role of Hydroxylamines in Drug-Induced Hemolytic Anemia 
Arylhydroxylamines are known to mediate the hemotoxic side-effects of hemolytic 
agents such as aniline, dapsone, propanil, and phenacetin (Harrison and Jollow, 1986; 















































Fig. 1.4. Effect of G6PD (A-) deficiency on the hemolytic activity of dapsone and 
primaquine in volunteers. PRIM (N) = primaquine in normal individuals, PRIM (A-) = 
primaquine in A- G6PD-deficient individuals, DDS (N) = dapsone in normal individuals, 
DDS (A-) = dapsone in A- G6PD-deficient individuals. 
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Fig. 1.5. Working Hypothesis for Arylhydroxylamine-induced Hemolytic Activity. AR-NOH = arylhydroxylamine; 
Hb++ = ferrohemoglobin; Hb+++ = ferrihemoglobin; HMP = hexose monophosphate shunt; SOD = superoxide dismutase 




believed that these metabolites evoke an oxidative stress within the red cell through a 
cyclic oxidation-reduction reaction (fig. 1.5) that involves oxyhemoglobin and molecular 
oxygen and yields the nitrosoarene, methemoglobin, and partially redl:lced forms of 
oxygen, respectively (Rostorfer and Cormier, 1957; Kiese, 1974). Based on EPR spin 
trapping experiments, these reactive oxygen species have been shown to further generate 
more reactive hydroxyl radicals and glutathione and hemoglobin thiyl radicals (Maples et 
aI., 1990; Bradshaw et aI., 1995; Bradshaw et aI., 1997) that are capable of critically 
damaging the red cell. In addition, this reaction is also believed to generate a 
phenylnitroxide radical intermediate through the one-electron oxidation of 
phenylhydroxylamine (Maples et aI., 1990). The nitrosoarene is subsequently reduced 
back to the hydroxylamine by NADPH-dependent reductase and is available to oxidize 
another equivalent of hemoglobin. Thus methemoglobin and activated oxygen species are 
produced in greater than stoichiometric amounts resulting in an oxidant stress within the 
red cell. 
Cellular Targets 
Although the precise intemallesion that ultimately marks a red cell for sequestration 
is not known, four major targets for oxidative attack have been proposed: 
1. Hemoglobin. As mentioned previously, several known and putative 
primaquine phenolic metabolites including 5-0H-PQ, 5,6-DHPQ, and 5,6-
HAQ have been shown to oxidize hemoglobin to methemoglobin. It is known 
that heme dissociates more readily from methemoglobin (Itano, 1970; 
Gutteridge, 1986) after which free globin precipitates easily. Denatured 
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hemoglobin is thought to attach to the plasma membrane to form Heinz 
bodies (Jacob, 1970). Heinz bodies have been reported to occur in red cells 
isolated from primaquine treated patients (Beutler et aI., 1954). The presence 
of Heinz bodies may mechanically impede the passage of erythrocytes 
through the spleen (Lubin and Desforges, 1972; Weinstein et aI., 1975), alter 
the adjacent membrane leading to splenic recognition and sequestration, or 
lead to splenic entrapment by inducing spherocyte formation due to splenic 
abstracting of the Heinz bodies along with membrane lipids known as a 
"pitting" process (Rifkind and Danon, 1965). Alternatively, heme oxidation 
may result in the release of iron in a free and diffusible form, which may 
catalyze the formation of hydroxyl radicals via the Fenton reaction (Ferrali et 
aI., 1992; Cic~oli et aI., 1994; Ciccoli et aI., 1999). Hydroxyl radicals are 
highly reactive, and can attack a number of intracellular sites, including 
membrane lipids and proteins. 
2. Sulfhydryl groups. Changes in cellular sulfhydryl status have long been 
associated with the premature sequestration of red blood cells. As 
demonstrated by Jacob et. al., titration of erythrocyte sulfhydryl groups with 
N-ethylmaleimide or p-chloromercuribenzoate causes the cells to be rapidly 
taken up by the spleen (Jacob and Jandl, 1962). In addition sulfhydryl 
oxidation may promote the formation of mixed disulfides between 
hemoglobin and glutathione and between hemoglobin and other cellular 
proteins. It has been suggested that these interactions cause a change in the 
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A second possible mechanism in which to elicit macrophage ingestion of damaged or 
aged erythrocytes includes disruption of the normal membrane phospholipid' 
asymmetrical distribution, in particular phosphatidyl serine (PS). Normally PS is 
maintained predominantly in the inner leaflet of the plasma membrane by the energy 
dependent transporter aminophospholipid translocase (i.e., flippase). Dissipation of the 
PS transbilayer gradient has been shown to play an important role in cell-cell recognition 
processes including macrophage recognition of apoptotic (Fadok et aI., 1992; Bratton et 
aI., 1997) and tumorigenic cells (Conner et aI., 1991; Utsugi et aI., 1991). Of interest, PS 
extemalization is also known to drastically enhance macrophage phagocytosis of red 
blood cells in vitro (Tanaka and Schroit, 1983; McEvoy et aI., 1986) as well as red cell 
clearance in vivo (Schroit et aI., 1985). In addition, aged, sickled, and uremic red cells 
(Conner et aI., 1994; Boas et aI., 1998) have been shown to contain PS in their outer 
membranes and to bind to macrophages more readily (Tait and Gibson, 1994; Wood et 
aI., 1996) than normal erythrocytes. It was hypothesized that PS exposure triggers 
macrophage recognition and ingestion of aged or damaged erythrocytes. 
Finally, the unmasking of a peptidic antigen that leads to opsonization by circulating 
autologous antibodies may signal a red cell for sequestration. A number of studies have 
suggested a key role for hemoglobin binding to cytoskeletal proteins in creating this 
antigenic site. In this regard, early observations by Morrison et. al. (Morrison et aI., 1983) 
of aged red cells included an increase in hemoglobin association with the cell membranes· 
prior to their sequestration. Low and colleagues later reported that hemoglobin avidly 
binds the cytoplasmic region of the integral membrane protein band 3 and stimulates its 
aggregation (Waugh and Low, 1985; Waugh et aI., 1986). In addition, these investigators 
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established that clustering of band 3 induced IgG opsonization and subsequent 
macrophage ingestion (Low et aI., 1985; Turrini et aI., 1991). These data lead to the 
hypothesis that as the red cells age or are damaged, hemoglobin binds to band 3 and 
initiates the formation of protein aggregates resulting in the more stable binding of 
autologous antibodies. Once a critical density of bound antibody is reached, complement 
binds and the cells are recognized by immunoglobulin and complement receptors on the 
macrophages and phagocytized. 
Rationale and Specific Aims 
While metabolites ~f primaquine have long been known to mediate the parent 
compound hemotoxic side effects (Tarlov et aI., 1962; Fraser and Vesell, 1968), the 
metabolic profile of primaquine remains poorly defined. The reasons for this are multi-
factorial beginning with primaquine having a molecular structure with multiple possible 
oxidation sites that gives rise to a large number of known and proposed metabolites (fig. 
1.2). Moreover, these metabolites are highly unstable in biological systems (Strother et 
aI., 1984; Idowu et aI., 1995). Adding to the complexity of this problem, Lee et a1. (Lee et 
aI., 1981) have demonstrated substantial species variations in sensitivity towards 
primaquine. For example, primaquine hemotoxicity has been particularly difficult to 
express in rats after both acute and chronic exposure (Bolchoz unpublished results, Lee et 
aI., 1981). Thus classical pharmacokinetic studies to identify potentially hemotoxic 
metabolites and determine the relative contribution to primaquine hemotoxicity are 
extremely difficult. 
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The long-term goal of our laboratory is to understand the mechanism underlyi:ng 
primaquine-induced hemolytic anemia. Therefore identification of the potentially 
hemotoxic metabolite(s) is crucial. As previous studies have suggested th~t drug-indu-ced 
hemolytic anemia is mediated by oxidative stress, the experimental approach is to 
identify redox active metabolites of primaquine that are potentially hemolytic. We intend 
to examine the metabolic formation of these derivatives, determine if they are hemolytic, 
and if so, to characterize the "pattern" of damage (i.e., the ratio of lipid to protein 
oxidation, change in morphology, effect on cellular sulfhydryl status, nature of radical 
formation) induced in rat red cells by these agents under hemolytic conditions. 
In addition to facilitating the effort to identify the hemotoxic metabolite(s) of 
primaquine, these studies will contribute significantly to the extensive efforts to elucidate 
the mechanism of drug-induced hemolytic anemia. In examining the extent to which 
these hemolytic agents induce the multiple intracellular lesions mentioned above, we can 
begin to assess the significance of these effects in the premature removal of red ceUs 
from the circulation. 
In contributing to this overall goal, the present studies examine the possible role of 6-
methoxy-8-hydroxylaminoquinoline (MAQ-NOH) in primaquine-induced hemolytic 
anemia. In doing so, we examined MAQ-NOH metabolic formation, hemolytic activity, 
and mechanism of inducing hemolytic anemia. The reasons for starting with the N-
hydroxy type metabolite are two fold. Previous studies in our laboratory have shown that 
the N-hydroxylated metabolites of hemolytic agents such as aniline, dapsone, propanil, 
and phenacetin are responsible for the parent compound hemotoxicity (Harrison and 
Jollow, 1986; Grossman and Jollow, 1988; Jensen and Jollow, 1991; McMillan et aI.., 
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1991). Secondly, 6-methoxy-8-aminoquinoline (6-MAQ), a logical precursor for MAQ-
NOH formation, is one of two known human primaquine metabolites (Baty et aI., 1975). 
Thus the following hypothesis and specific aims were developed: 
Hypothesis: The primaquine metabolite, MAQ-NOH, induces hemolytic anemia in the 
rat by initiating an oxidative stress within the red cell that alters the red cell membrane 
integrity. 
Specific Aim 1. 1) To establish if 6MAQ is metabolized to MAQ-NOH using rat and 
human microsomes. 2) To determine the potency of MAQ-NOH with respect to 
hemolytic and methemog1.obinemic activity. 
Specific Aim 2. To examine the morphological and oxidative effects of MAQ-NOH in 
rat erythrocytes in the presence and absence of aSH focusing on lipid peroxidation and 
membrane skeletal protein damage. 
Specific Aim 3. To identify the radical species formed in response to MAQ-NOH in rat 
erythrocytes under hemolytic conditions. 
CHAPTER 2 
Primaquine-induced Hemolytic Anemia: Formation and Hemotoxicity of the 
Ary lhyroxylamine Metabolite 6-Methoxy -8-hydroxylaminoquinoline 
35 
Introduction 
Malaria is considered to be the most widespread parasitic infection in the world, with 
nearly one third of the world population threatened by Plasmodium sp. infections (Miller, 
1997). Primaquine, an 8-aminoquinoline drug, has been an important antimalarial agent for 
over 40 years because of its unique effectiveness against exoerythrocytic forms of the 
parasite. Primaquine is currently the only drug capable of treating the persistent liver stages 
of P. vivax and P. ovale responsible for relapsing malaria (Tracy and Webster, 1996). 
Furthermore, the importance of primaquine has grown recently due to development of 
resistance against other antimalarial drugs, and because of its potential for use against 
opportunistic Pneumocystis cannni pneumonia in AIDS patients (Kantor, 1992). 
Despite its broad antiparasitic activity, primaquine therapy is limited by its capacity to 
induce a Heinz-body anemia, particularly in individuals with deficiency in erythrocytic 
glucose-6-phosphate dehydrogenase (G6PD) activity (Dem et al., 1955; Degowin et al., 
1966). Deficiency in erythrocytic G6PD has been shown to confer resistance to infection 
by the malarial parasite, which presumably accounts for the high incidence of G6PD 
deficiency in areas endemic for malaria (Beutler, 1978). Early mechanistic studies 
established that 1) primaquine hemotoxicity was due to metabolite(s) of the drug, rather than 
the parent compound; 2) glutathione became oxidized to glutathione disulfide and was lost 
from the red cell; 3) hemoglobin became denatured and formed large insoluble aggregates 
that were attached to the inner surface of the red cell membrane (Le., Heinz bodies); and 4) 
the hemolytic activity was associated with an accelerated removal of the damaged (but intact) 
red cells from the circulation by the spleen and liver (for review, see Beutler, 1969). The 
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identity of the hemotoxic metaboIite(s), however, was not detennined, and the mechanism 
underlying the hemolytic response to primaquine remains unknown. 
Phenolic metabolites of primaquine have long been suggested as candidate hemotoxic 
species (Tarlov et aI., 1962). These oxidation products have been identified as metabolites of 
primaquine in the biological fluids of experimental animals (Strother et aI., 1981; Strother et 
al., 1984; Idowu et al., 1995), and they have been observed to cause oxidative damage to 
nonnal and G6PD-deficient erythrocytes (Strother et al., 1984; Agan.val et al., 1988; 
Fletcher et al., 1988). However, phenolic metabolites have not been detected in humans after 
administration of primaquine (Baty et al., 1975; Mihaly et al., 1984) or in primaquine-
treated human liver microsomes (Bangchang et aI., 1992). 
An alternate hypothesis is that the hemotoxicity of primaquine is associated, in part or in 
whole, with an arylhydroxylamine metabolite. Primaquine is known to undergo N-
dealkylation in humans to yield 6-methoxy-8-aminoquinoline (6-MAQ) (Baty et al., 1975). 
In previous studies with other arylamines, such as aniline and dapsone, we have observed 
that their N-hydroxy metabolites are direct-acting hemotoxicants and are responsible for the 
hemolytic activity of the parent compounds (Harrison and Jollow, 1986; Grossman and 
JoBow, 1988). It is thus plausible that 6-MAQ could be converted to its N-hydroxy analog 
(fig. 2.1), and that this metabolite could be capable of inducing methemoglobinemia and 
hemolytic damage. 
To investigate whether an arylhydroxylamine metabolite could be involved In 
primaquine hemotoxicity, we have synthesized the putative N-hydroxy metabolite, 6-
methoxy-8-hydroxylaminoquinoline (MAQ-NOH), and have examined the capacity of rat 
and human liver microsomes to form this metabolite. In addition, we have assessed the 
ability of MAQ-NOH to induce methemoglobin formation and hemolytic damage in rat 
erythrocytes. We report that MAQ-NOH was fonned in both rat and human liver 
mi cro somes , and that MAQ-NOH is a direct-acting methemoglobinemic and hemolytic 


















obtained (fig. 2.2) with chemical shifts (in ppm referenced to the solvent) at 3.86 (s, 3H, 6-
OCH3), 6.92 (d, 1=2.5 Hz, IH, Hs), 6.96 (d, 1=2.5 Hz, IH, H7), 7.74 (dd, 1=4.8 Hz,1=8.4 
Hz, IH, H3), 8.59 (d, 1=8.4 Hz, IH, 14), 8.77 (dd, 1=1.5 Hz, 1=4.7 Hz, 1H, H2); the 8-
amino protons were not observed. 
MAQ-NOH was synthesized as previously described (Allahyari et al., 1984). Breifly, 
40 mg of platinum oxide in 13.33 ml of ethyl acetate was reduced for in a Parr 
hydrogenator for 5 min under 12 psi of hydrogen. Next, 4 grams of 6-methoxy-8-
nitroquinoline in 93.3 ml of ethyl acetate was added to a suspension and reduced for 1 hour 
at 31 psi. The reaction was cooled in the freezer overnight and the precipitate was 
recrystallized once from acetone. HPLC analysis of the product showed <1 % residual 6-
methoxy-8-nitroquinoline. Mass spectral analysis (fig. 2.3) revealed a molecular ion (M+) 
at mlz 191, and a predominant fragment ion at mlz 175. MSIMS analysis of the M+ 
revealed fragment ions at mlz 176 (M+ -15), 173 (M+ -18), and 162 (M+ -29). The NMR 
spectrum of MAQ-NOH (fig. 2.4) showed chemical shifts at 3.84 (s, 3H, 6-0CH3), 6.69 
(d, 1=2.7 Hz, IH, H5), 6.76 (d, 1=2.7 Hz, IH, H7), 7.43(dd, 1=4.2 Hz, 1=8.3 Hz, IH, H3), 
8.13 (dd, 1=1.6 Hz, 1=8.3 Hz, IH, R4), 8.56 (dd, 1=1.7 Hz, 1=4.2 Hz, IH, H2), 8.67 (s, IH, 
-NH), 8.79 (8, IH, -NOH). DQ-COSY analysis of the cross peaks confirmed the 
assignment of the aromatic ring protons. The synthetic compounds were stable under argon 
at-80°C. 
HPLC Analysis 
Chromatography was performed on a Waters HPLC system (Waters Assoc., Milford, 
MA) consisting of a Model 6000A pump, a Rheodyne injector (20 JlI loop) and a 250 rom 
Altech Platinum EPS CI8 reverse,..phase column. 6-MAQ was eluted with 35% acetonitrile 
in water at a flow rate of 1.2 m1Imin, and was detected on a Waters model 481 IN-Vis 
variable wavelength detector set at 280 nm. MAQ-NOH was eluted with 40% methanol in 
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Fig. 2.3. (A) ESI mass spectrum of synthetic MAQ-NOH. (B) ESI MSIMS 
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1.5 mUrnin, and was detected using either 1) a Bioanalytical Systems (West Lafayette, IN) 
LC-4B electrochemical detector equipped with a glassy carbon working electrode (oxidation 
mode, +0.35 volts) and a Ag/AgCI reference electrode; or 2) a Waters Millennium model 
996 photodiode array detector. 
NMR Spectroscopy and Mass Spectrometry 
Mass spectral analysis was performed on a Finnigan LCQ Quadrapole ion trap tandem 
mass spectrometer. The instrument was operated in positive-ion mode with electrospray 
io~zation (ESI) needle voltage, 4.2 kV; ESI capillary temperature, 200oe; isolation width, 2 
amu; scan range 100-500 amu. MSIMS data was simultaneously acquired for the selected 
parent ion (mlz 191). Helium was used to fragment the ion with a collision parameter set to 
35. Proton NMR spectra were acquired on a Varian VXR 400 spectrometer operating at 400 
MHz with conventional quadrature detection. 
Microsomal metabolism of6-MAQ 
6-MAQ (1 mM) was incubated with male Sprague-Dawley rat and pooled human liver 
microsomes (1.0 mg proteinlml) in 100 mM phosphate buffer pH 7.4. The reaction was 
initiated by the addition of an NADPH generating system (163 J.tM B-NADP+, 1.7 mM-
glucose-6-phosphate, and 0.375 U glucose-6-phosphate dehydrogenase). The incubation 
was conducted in a shaking water bath at 37°C. Aliquots (100 JLl) were removed at 1, 3,,5, 
10, 20, and 30 min, added to 100 J.tl of cold methanol and centrifuged at 13,500 x g for 1 
min. An aliquot of the supernatant (20 J.tl) was then injected immediately into the HPLC for 
analysis. The concentration of MAQ-NOH in the microsomal incubations was quantified 
by measuring the peak height against a standard curve obtained by addition of synthetic 
MAQ-NOH to microsomal protein. 
To obtain a mass spectrum of the microsomal metabolite, three microsomal suspensions 
(1 ml) were concentrated using Oasis lll..B 1 cc CI8 Extraction Cartridges (Waters Assoc., 
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Milford, MA). The cartridges were washed with 1 ml of methanol and equilibrated with 1 ml 
of water. After loading the microsomal incubation on the cartridge, it was washed with 5% 
methanol/water. The metabolite was eluted with 1 m1 of 100% methanol and dried in a 
Speed Vac Concentrator. The three samples were then pooled and dissolved in 750/0 
methanol/water, and injected onto the HPLC. The peak corresponding to the metabolite was 
collected, and an aliquot was injected directly into the ion source of the mass spectrometer 
for analysis. 
Hemotoxicity Studies 
The level of methemoglobin in erythrocyte suspensions treated with MAQ-NOH (100-
2,500 JIM) was measured as described previously (Harrison and Jollow, 1987). Briefly, 100 
Jll aliquots of the red cell suspensions were added to 5 ml of hemolysis buffer (0.277% 
potassium phosphate monobasic, 0.289% sodium phosphate dibasic, and 0.05% Triton X-
100; pH7.8). The hemolyzed solution was divided into four 1 ml aliquots; 20 JlI of 10% 
KeN was added to the second and forth aliquots, and 20 Jll of 20% KFe(CN)6 was added 
to the third and forth aliquots. The absorbance of each aliquot was detennined at 635 nm. 
The percent methemoglobin of total hemoglobin was calculated as %methemoglobin = 
(A 1-A2)/( A3-A4» 1 00. 
The survival of 51Cr-labeled red cells was detennined in vivo after in vitro exposure to 
various concentrations of MAQ-NOH (0-750 JLM) as described previously (Harrison and 
Jollow, 1986). Briefly, MAQ-NOH dissolved in DMSO (10 JII) was added to erythrocyte 
suspensions (40% red cells, 2.0 ml) and allowed to incubate aerobically for 2 hr at 37°C. 
After the incubation, the red cells were washed once, resuspended in PBSG, and 0.5 rn1 
aliquots were administered intravenously to isologous rats. Thirty minutes after 
administration of the labeled red cells a TO blood sample was taken from the orbital sinus, 
and then serial samples were taken at 48 hr intervals for 14 days. At the end of the 
experiment, the radioactivity in the blood samples was counted concurrently in a well-type 
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gamma counter, and the counts above background were expressed as percentage of the To 
sample. The time for blood radioactivity to decrease to 50% of initial levels (51CrT50) was 
determined for each animal by regression analysis. Statistical significance was detennined 
with the use of Student's t-test. 
To detennine the hemolytic activity of MAQ-NOH in vivo, untreated 51Cr-Iabeled red 
cells were administered intravenously to isologous rats. A TO blood sample was taken via 
the orbital sinus 48 hr after administration of the labeled cells. MAQ-NOH (150 and 250 
mg/kg, i.p.) dissolved in DMSO (0.5 ml/kg, i.p.) was administered immediately after the TO 
blood sample was taken. Serial blood samples were taken at the designated intervals and 
assayed as described above for the in vitro incubation/in vivo survival protocol. 
Results 
Microsomal Metabolism of6-MAQ 
To determine whether an N-hydroxy metabolite of 6-MAQ could be formed by rat and 
human liver microsomes, 6-MAQ (1 mM) was incubated with liver microsomes (1 mglml) 
containing an NADPH-generating system for 3 min at 37°C. At the end of the incubation 
period, an aliquot (100 JlI) was removed, added to ice-cold methanol (100 JLI) and 
centrifuged. An aliquot of the supernatent (20 JlI) was then injected immediately onto the 
HPLC-EC. As shown in fig. 2.5C, a single chromatographic peak was observed from the rat 
microsomal sample. This peak was not observed in the absence of an NADPH-generating 
system (fig. 2.5B). The retention time of the metabolite peak was identical to that of 
synthetic MAQ-NOH (fig. 2.5A), and its UV-visible absorbance spectrum also was 
identical (data not shown). Formation of the metabolite was time dependent, being linear for 
about 3-5 minutes (fig 2.6A). 
To confirm the identity of the microsomal metabolite, rat microsomal incubations were 

























o 5 10 o 5 10 
Retention time (min) 
Fig. 2.5. HPLC-EC detection of MAQ-NOH. (A) Synthetic MAQ-NOH standard (1 
Jlmol/ml); (B) 6-MAQ (1 mM) incubated for 3 min in rat liver microsomes without an 
NADPH-generating system; (C) 6-MAQ incubated for 3 min in rat liver microsomes with 
an NADPH-generating system; (D) 6-MAQ incubated for 3 min in human liver 
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Fig. 2.6. (A) Time-dependence of MAQ-NOH formation in rat and human liver 
microsomes incubated with 6-MAQ (1 mM). Data points are means of duplicate 
incubations. (B) Stability of MAQ-NOH in buffer and microsomes. Synthetic MAQ-
NOH was added to phosphate buffer (pH 7.4) or rat liver microsomes that did not contain 
an NADPH-generating system. Aliquots were withdrawn at designated intervals and the 
amount of MAQ-NOH remaining vs. time was quantified by HPLC-EC. Values are 
means of duplicate incubations. 
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MS analysis, three separate microsomal incubations were canied out with 6-MAQ (0.1 
mM) for 10 min, and then the reaction mixtures were pooled and subjected to solid-phase 
extraction. The extract was concentrated in a Speed Vac, injected onto the HPLC, and the 
metabolite peak was collected and injected into the mass spectrometer. The mass spectrum 
of the metabolite (fig. 2.7 A) showed a molecular ion at mlz 191, consistent with the addition 
of an hydroxyl group on 6-MAQ. A fragment ion at mlz 175 (M+-16, -0) was also 
observed, indicating the loss of elemental oxygen from the molecular ion. This loss of 16 
mlz units has been observed previously with other N-hydroxyarylamine compounds (Lay 
et. aI., 1986). The molecular ion (mlz 191) was then selected and subjected to ESI MS/MS. 
The MSIMS spectrum of the microsomal metabolite (fig. 2.7B) showed three fragment ions 
at mlz 176 (-15; -CH3), 173 (-18; -H20), and 162 (-29; -CHO). This fragmentation 
pattern was also seen in the MSIMS of synthetic MAQ-NOH. 
Incubation of 6-MAQ with human microsomes in the presence of NADPH (fig. 2.5D) 
resulted in the fonnation of a metabolite with the same retention time and UV spectrum as 
that of the rat (fig. 2.5C). The fonnation of MAQ-NOH by human microsomes was linear 
for about 5 minutes (fig. 2.6A). Of interest, the extent of fonnation of MAQ-NOH by 
human microsomes was about twice that of rat microsomes. 
Parallel stability studies, in which a known amount of MAQ-NOH was added to rat 
microsomal suspensions, indicated that MAQ-NOH disappeared in an apparent first-order 
manner with a Tl/2 of about 6 minutes (fig. 2.6B). Thus it is likely that the observed 
production of MAQ-NOH in rat and human microsomal suspensions is an underestimation 
of the enzymatic capacity of the microsomes to N-oxidize 6-MAQ. 
In vivo hemolytic activity of MAQ-NOH 
To examine the hemolytic potential of MAQ-NOH in vivo, groups of rats were infused 
with 51Cr-Iabeled erythrocytes 48 hr before i.p. administration of various doses of MAQ-
NOH (dissolved in DMSO) or the vehicle alone. After an initial blood sample (To), serial 
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Fig. 2.7. (A) ESI mass spectrum of the 6-MAQ metabolite formed In rat liver 
microsomes. (B) ESI MSfMS of the parent ion (mlz 191). 
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blood samples were obtained to allow detennination of the time necessary for the 
radioactivity to decline to 50% of the To value (51Cr-Tso) for each animal. As shown in fig. 
2.8, vehicle-treated controls exhibited a gradual decline in blood radioactivity (51Cr-Tso of 
9.27 ± 0.34 days) that is considered to reflect primarily the normal removal of senescent 
erythrocytes. Erythrocyte survival after administration of a 150 mglkg (0.94 mmol/kg) dose 
ofMAQ-NOH was not significantly different from controls. However, the 250 mglkg (1.57 
rnmol/kg) dose produced a statistically significant increase in the rate of removal of the 
radiolabeled erythrocytes (51Cr-T50 ~f 6.36 + 1.1 days). Unfortunately, administration of 
higher doses of MAQ-NOH (>300 mglkg) were lethal due to acute respiratory depression, 
which precluded the construction of a complete dose-response curve for MAQ-NOH 
hemolytic activity in vivo. 
Direct Hemotoxicity of MAQ-NOH 
To detennine if MAQ-NOH acts directly upon red cells to produce hemolytic damage, 
rat Sler-Iabeled erythrocytes were resuspended in PBSG (40% hematocrit) and incubated 
with various concentrations of MAQ-NOH in vitro for 2 hr at 37°C. No evidence for 
hemolysis was observed under these incubation conditions. The cells were then washed 
once, administered intravenously to isologous rats, and serial blood samples were taken for 
15 days. As shown in fig. 2.9A, exposure of the labeled cells to MAQ-NOH induced a 
concentration-dependent increase in the rate of removal of radioacti vity from the blood as 
compared to controls. The concentration-dependence of this response is shown in fig. 2.9B; 
the hemolytic response is plotted as the percentage reduction in the 51Cr-T50 of the 
experimental animals relative to the mean control value. The EC50 under these experimental 
conditions was about 350 jLM. In contrast to MAQ-NOH, treatment of 51er-Iabeled 
erythrocytes with 6-MAQ (1.5 mM) did not increase significantly the rate of removal of 
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Fig. 2.8. Effect of administration of MAQ-NOH to rats on the survival of 51Cr-labeled 
erythrocytes in vivo. Isologous rats recei ved untreated radiolabeled erythrocytes 
intravenously 48 hr before i.p. administration of the indicated doses of MAQ-NOH 
dissolved in DMSO; control rats were injected with vehicle alone. To blood samples were 
obtained from the orbital sinus immediately before MAQ-NOH administration. Data 
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Fig. 2.9. (A) Survival of slCr-labeled erythrocytes in vivo after in vitro exposure of the 
labeled cells with MAQ-NOH. Radiolabeled erythrocytes were incubated for 2 hr at 37°C 
with the indicated concentrations of MAQ-NOH; control cells were incubated with 
vehicle (10 pJ DMSO) alone. The erythrocytes were then washed and administered 
intravenously to isologous rats. To blood samples were taken 30 min after administration 
of the labeled cells. Data points are means ± SD (n=4). (B) Concentration-response 
relationship for reduction in the Tso of slCr-labeled erythrocytes after MAQ-NOH 
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Fig. 2.10. (A) Methemoglobin formation vs. time in rat erythrocytes treated with the 
vehicle (DMSO, 10 Jll) or MAQ-NOH (750 JlM). Data points are means ± SD (n=4). (B) 
Concentration dependence of the methemoglobinemic response to MAQ-NOH. Peak 
methemoglobin, the maximal level of methemoglobin achieved for each incubation. Data 
points are means ± SD (n=4). 
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To examine the capacity of MAQ-NOH to induce methemoglobinemia in vitro, the 
time- and concentration-dependence of methemoglobin fOITIlation was examined in rat 
erythrocyte suspensions exposed to MAQ-NOH. As shown in fig. 2.10A, incubation of 
erythrocyte suspensions with MAQ-NOH (750 JLM) resulted in the rapid fonnation of 
methemoglobin. Methemoglobin levels reached a peak of about 250/0 within an hour af 
MAQ-NOH exposure, and then declined gradually over the next 2 hrs. In contrast, the level 
of methemoglobin in control incubates remained low and constant during the course of the 
experiment. The MAQ-NOH concentration dependence of this response after 60 min· of 
incubation is shown in fig. 2.7B. Methemoglobin levels under these conditions ranged from 
about 100/0 methemoglobin at 100 JLM MAQ-NOH up to about 65% methemoglobin at 2.5 
mMMAQ-NOH. 
Discussion 
The present results demonstrate that 6-MAQ, a known human metabolite of primaquine,. 
can be N-hydroxylated to form MAQ-NOH by both rat and human liver microsomes (fig. 
2.5e and D). Incubation of rat red cells with this metabolite caused a concentration ... 
dependent formation of methemoglobin (fig. 2.10B). When 51er-tagged red cells were. 
incubated with MAQ-NOH, washed, and then administered to isologous rats, survival of the 
tagged red cells in the circulation was reduced in a concentration-dependent manner. Under 
the incubation conditions chosen (aerobic for 2 hr at 37°C in buffer containing glucose)" no 
evidence for frank hemolysis was observed, and the EC50 for the hemolytic response was 
about 350 JLM MAQ-NOH (fig. 2.9B). Furthermore, MAQ-NOH was able to provoke a 
hemolytic response when administered directly to rats (fig. 2.8). 
Although the crucial role of metabolism in primaquine hemotoxicity has been accepted 
for over 40 years (Fraser and Vesell, 1968), the hemotoxic metabolite(s) have not been 
identified. Lack of progress is due in large part to the multiplicity of the known and 
proposed pathways of primaquine metabolism (fig. 1.2), all of which can give rise to 
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metabolites with redox potential. Moreover, poor organic solubility and instability of these 
putative metabolites have complicated their extraction and quantification from biological 
media (Idowu et al., 1995). These obstacles, combined with the difficulty in provoking a 
hemolytic response in laboratory animals with primaquine (Lee et aI., 1981; Jollow et aI., 
unpublished studies), have hampered efforts to determine the contribution each metabolite 
makes towards methemoglobin formation and hemolytic damage in vivo. 
To overcome these problems, investigators have synthesized phenolic derivatives of 
primaquine and have examined their effects in erythrocyte suspensions. Following the 
suggestion of Tarlov and colleagues (Tarlovet aI., 1962), much attention has been given to 
the 5-hydroxy- and 5,6-dihydroxy metabolites of primaquine (fig. 1.2), which (via 5,6-
quinone formation) could support redox cycling and the generation of active oxygen species 
(Link et al., 1985). In support of this postulate, these compounds were shown to induce a 
variety of oxidative effects in both normal and G6PD-deficient red cells, including 
stimulation of hexose monophosphate shunt activity (Baird et al., 1986), hemoglobin 
oxidation and GSH depletion (Strother et al., 1981; Agruwal et al., 1988; Fletcher et al., 
1988). More recently, Vasquez-Vivar and Augusto (1994) showed that a 500 JLM 
concentration of the quinoneimine derivatives of these metabolites (prepared by treatment of 
the phenols with hydrogen peroxide) could induce oxidative damage and increase the 
osmotic fragility of rat erythrocytes. When examined under the same experimental 
conditions, 6-MAQ was found by these investigators to be inactive. Thus, they concluded 
that phenolic metabolites were the toxic species and that an N-hydroxylated metabolite was 
unlikely to contribute to the hemotoxicity of primaquine. However, MAQ-NOH was not 
synthesized in these studies and tested directly, and it is not clear that sufficient levels of 
MAQ-NOH could have been generated from 6-MAQ under their experimental conditions 
to allow adequate test of the postulated role of this metabolite. Moreover, since hemolytic 
anemia in humans is associated with sequestration of intact red cells rather than with 
intravascular hemolysis (Rifkind, 1966), the relevance of their observed increases in osmotic 
fragility is uncertain. 
While the in vivo survival data in fig. 2.9 clearly indicates that MAQ-NOH is directly 
hemolytic to G6PD-nonnal rat red cells, these data do not allow for direct assessment of the 
role of MAQ-NOH in primaquine hemotoxicity. It is noteworthy, however, that the pattern 
of the response produced by MAQ-NOH exposure; i.e., the rate of Sler uptake with no 
evidence of frank lysis, was similar to that observed with arylhydroxylamine metabolites of 
aniline and dapsone. The type of damage inflicted by these direct-acting hemolytic agents 
has been shown to be consistent with an acceleration of the normal removal of "aged" but 
intact red cells from the circulation by the spleen (Jollow and McMillan, 1998). The 
hemolytic potency of MAQ-NOH (ECso 350 JlM) towards G6PD-normal rat red cells, as 
measured in the in vitro/in vivo assay, was about 2-fold lower than that of dapsone 
hydroxylamine (ECso ca. 150 JlM) which mediates the hemolytic activity of dapsone 
(Grossman and Jollow, 1988), and about three-fold more potent than N-hydroxyphenetidine 
(EC50 ca. 900 p,M), which mediates the hemotoxicity of phenacetin (Jensen and Jonow, 
1991). 
The in vitro exposure/in vivo erythrocyte survival assay allows the hemolytic damage 
observed in vivo to be reproduced in vitro under controlled conditions during a 2-hr 
incubation period before the cells are returned to the circulation of isologous rats, and thus 
is a useful indicator of relative hemolytic potency among direct-acting hemolytic agents. 
However, this assay cannot be utilized to define the MAQ-NOH blood concentrations 
needed to cause a hemolytic response in vivo. Previous studies with dapsone hydroxylamine 
have demonstrated that hemolytic activity is proportional to the AVe of the metabolite and 
is not dependent on its concentration (Grossman and Jollow, 1988). Since the half-life of 
primaquine in humans is about 6 hours (Fletcher et al., 1981), it is likely that 6-MAQ and 
the secondary metabolite, MAQ-NOH, will be produced at a low but steady rate during 
chronic primaquine therapy. Thus, while the concentration of MAQ-NOH in the circulation 
57 
may never be very high, its AVe may be appreciable and reach toxicologically significant 
levels in G6PD-deficient patients. 
Assessment of the contribution that MAQ-NOH makes to primaquine hemotoxicity is 
further complicated by the probability that the putative phenolic metabolites discussed above 
are fonned in humans and hence also have the potential to induce hemolytic injury. In 
preliminary studies using the in vitro exposurelin vivo erythrocyte survival assay, we have 
observed that both 5-hydroxyprimaquine and 5-hydroxy-6-desmethylprimaquine are direct-
acting hemolytic agents with hemolytic potencies similar to that of MAQ-NOH 
(unpublished results).' Thus, primaquine could be metabolized to three types of hemotoxic 
species: phenolic, diphenolic and arylhydroxylamine, each of which would be capable of 
undergoing redox cycling within the red cell. 5-Hydroxyprimaquine forms a redox pair with 
its p-quinoneimine analog, the 5,6-diphenolic metabolite with either an o-quinone or a p-
quinoneimine, and the 8-hydroxylamino metabolite (i.e., MAQ-NOH) with its nitroso 
analog. These considerations emphasize the need for more detailed studies on the 
metabolism of primaquine in rats and humans, and raise the possibility that more than one 
type of metabolite is responsible for primaquine hemotoxicity. 
In the present studies on the metabolism of 6-MAQ, we did not detect a phenolic 
metabolite in either rat or human microsomal incubations. This does not indicate that these 
metabolites are not fanned, but does raise the possibility that either they may not be major 
contributors to the hemotoxicity of 6-MAQ, or that their instability is much greater than that 
of MAQ-NOH under these experimental conditions. Further experiments will be necessary 
to determine whether phenolic metabolites of primaquine can be detected in humans. In 
addition, the effect of CYF inducers and inhibitors on the metabolism of primaquine and 6-
MAQ will be necessary to identify' CYP isoforms responsible for toxic vs. non-toxic 
pathways, and will be crucial in the development of a primaquine-sensitive animal model. 
In regard to the mechanism underlying primaquine-induced hemolytic anemia, data 
published by Degowin et al. (1966) first raised' the possibility that oxidative damage to 
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erythrocytes could anse by different mechanisms depending -on the oxidant. These 
investigators reported that the doses of primaquine necessary to evoke signs of hemolysis in 
A- G6PD-deficient volunteers are about 20-fold lower than those required to elicit a similar 
response in G6PD-normal volunteers, whereas the doses of dapsone required to induce 
similar responses in G6PD-deficient vs. normal differ only by a factor of two. Although the 
underlying basis for these differences is not clear, it may b~ explained by the fact that 
dapsone hemotoxicity is mediated solely by N-hydroxy metabolites, whereas primaquine 
hemotoxicity could be mediated by multiple hemotoxic species, quinone, quinoneimine, and 
arylhydroxylamine (fig. 1.2). Clearly, a quantitative assessment of the contribution each 
type of metabolite makes towards the hemotoxic response will be important in elucidating 
the mechanism underlying primaquine-induced hemolytic anemia. 
In summary, we have demonstrated that a known hUn;J.an metabolite of primaquine, 6-
MAQ, can be N-hydroxylated by both rat and human liver microsomes, and that this N-
hydroxy metabolite is hemolytic in vivo in rats, and is directly hemotoxic to the rat red blood 
cell. The contribution of this metabolite to primaquine hemotoxicity remains to be assessed. 
CHAPTER 3 
Primaquine-Induced Hemolytic Anemia: Effect 6-Methoxy-8-
Hydroxylaminoquinoline on Rat Erythrocyte Sulfhydryl Status, Membrane Lipids, 
Cytoskeletal Proteins and Morphology 
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Introduction 
The antimalarial drug primaquine has been the drug of choice for the treatment of the 
exoerythrocytic forms of Plasmodium vivax and P. ovale for more than 40 years (Tracy 
and Webster, 1996). Recently, primaquine has also been utilized for its gametocytocidal 
activity against P. Jalciparium to help combat widespread drug resistance of this species 
to blood schizonticides, such as chloroquine (Peters, 1999). Furthermore, primaquine is 
used to treat mild to moderate cases of Pneumocystis cannni pneumonia in patients with 
acquired immunode~iciency syndrome (Toma et aI., 1998). Despite the clinical 
importance of primaquine, its therapeutic use is limited by its toxic side-effects, 
hemolytic anemia and methemoglobinemia (Dern et aI., 1955; Degowin et aI., 1966). 
The mechanism by which primaquine induces hemolytic anemia remains elusive. 
Early mechanistic studies established that: 1) metabolite(s) of primaquine are the toxic 
species; 2) GSH is lost from the red cell prior to a hemolytic response; 3) denatured 
hemoglobin aggregates (i.e., Heinz bodies) are associated with the red cell membrane; 
and 4) hemolytic anemia is particularly pronounced in individuals who are deficient in 
glucose-6-phosphate dehydrogenase (G6PD) activity (for review, see Beutler, 1969). 
Collectively, these observations led to the concept that primaquine-induced hemolytic 
anemia is caused by oxidati ve stress. However, the identity of the toxic primaquine 
metabolites and the nature of the oxidant stress are not known. 
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We have reported recently that the known human primaquine metabolite, 6-methoxy-
8-aminoquinoline (6-MAQ), can be N-hydroxylated to form 6-methoxy-8-
hydroxylaminoquinoline (MAQ-NOH) by both rat and human microsomes (Bolchoz et 
aI., 2001). Furthermore, MAQ-NOH was found to be a direct-acting hemolytic agent in 
the rat; that is, when rat 51Cr-Iabeled red cells are incubated with MAQ-NOH in vitro and 
returned to isologous rats, the labeled red cells are more rapidly removed from the 
circulation than are the vehicle-treated control cells. 
Although sequestration of senescent or damaged (but intact) red cells from the 
circulation is known to occur by macrophages of the reticuloendothelial system (Rifkind, 
1966), the signal that marks these cells for removal remains unknown and continues to be 
a subject for debate (for review, see Bratosin et aI., 1998), One group of studies suggests 
that peroxidative damage ,to the plasma membrane lipid bilayer transmits the signal for 
sequestration (Lubin and Chiu, 1982; Zwaal and Schroit, 1997). Alternatively, membrane 
skeletal protein alterations may underlie the removal process. For example, alteration in 
the lateral distribution of band 3 protein via hemoglobin (or hemichrome) binding has 
been shown to result in the binding of autologous antibodies, which commit the cells for 
uptake by cultured monocytes (Waugh et aI., 1987; Turrini et aI., 1991). 
In view of the critical role proposed for oxidant damage in the mechanism underlying 
primaquine-induced hemolytic anemia, we have examined the effect of MAQ-NOH on 
sulfhydryl status, membrane lipids and skeletal proteins in suspensions of rat erythrocytes 
using MAQ-NOH concentrations known to induce the premature removal of these cells 
from the circulation. We report that MAQ-NOH has only a modest capacity to oxidize 
red cell GSH to GSSG and as-protein mixed disulfides, and to induce the formation of 
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hemoglobin-skeletal protein adducts. In contrast to other arylhydroxylamines, exposure 
of normal rat red cells to MAQ-NOH significantly enhanced the peroxidation of 
membrane lipids. When aSH was depleted from rat red cells to mimic the low levels of 
aSH that are observed in the human G6PD-deficient red cell (Gaetani et al., 1979), the 
hemolytic activity of MAQ-NOH was markedly enhanced. This exacerbation was 
associated with the development of protein thiol oxidation without change in the level of 
lipid peroxidation. It is suggested that MAQ-NOH can inflict hemolytic injury on the red 
cell by two pathways; lipid peroxidation in GSH-normal red cells and protein oxidation 
in GSH-depleted red cells. The possibility of synergistic interaction between these 
processes and among the hemotoxic metabolites of primaquine is discussed. 
Materials and Methods 
Chemicals and Materials 
MAQ-NOH was synthesized as described previously (Allahyari et al., 1984). 
Malondialdehyde, diethyl maleate (DEM), and rabbit anti-rat hemoglobin IgG were 
purchased from Sigma Chemical Co. (St Louis, MO). HRP-conjugated donkey anti-rabbit 
IgG was purchased from Amersham Pharmacia (Piscataway, NJ). Na251Cr04 in sterile 
saline (1 mCi/ml, pH 8) was obtained from New England Nuclear (Billerica, MA). All 
other chemicals were of the best commercially available grade. 
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Animals 
Male Sprague-Dawley rats (75-100 g) were purchased from Harlan Laboratories 
(Indianapolis, IN) and were maintained on food and water ad libitum. Animals were 
acclimated to a 12-hr light-dark cycle prior to their use. 
Red Cell Incubation Conditions 
Blood from the descending aorta of anesthetized rats was collected into heparinized 
tubes and washed in isotonic phosphate-buffered saline (pH 7.4) supplemented with 10 
mM D-glucose (PBSG). After removal of the plasma, the red cells were resuspended in 
PBSG to a 40% hematocrit and used the same day they were collected. Experiments were 
carried out by addition of various concentrations of MAQ-NOH dissolved in DMSO (lO 
ttl) to the erythrocyte suspensions (2 ml) and allowed to incubate at 37°C for up to 2 hr. 
Detennination of Sulfhydryl Status 
GSH content was determined as described previously (Grossman et aI., 1992). 
Aliquots (0.2 ml) of the incubation mixtures were lysed with 800 Jd of cold EDTA (1 
mM) and the protein precipitated with 500 pJ of 25% sulfosalicylic acid. Following a 5 
min incubation on ice, the protein was pelleted at 10,000 rpm for 2 min. To assay for 
GSH, 500 JlI of the supernatant was added to 1 ml of Tris-acetate buffer (0.5 M; pH 7.6) 
and 2 ml of phosphoric acid (1 M). GSH content was analyzed by HPLC with 
electrochemical detection as described below. 
To detennine GSSG, 500 JlI of supernatant was added to 1 ml of Tris-acetate buffer 
(0.5 M; pH 7.6) and 10 Jll of n-octanol. The mixture was incubated with sodium 
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borohydride (50 mg) at 37°C for 30 min. After incubation, the mixture was chilled, 2 ml 
of phosphoric acid (1M) was added, and GSH content analyzed. 
To determine GS-protein mixed-disulfides the protein pellet was washed with 25% 
sulfosalicylic acid, suspended in a solution containing 2.970 m! of 25% sulfosalicylic 
acid, 15 JLl Triton X-100, and 15 III Antifoam, homogenized for 30 sec in a Polytron 
homogenizer (Brinkman), and centrifuged at 15,000 rpm for 10 min. The pellet was 
treated with sodium borohydride (50 mg), homogenized for 30 sec, and incubated at 37°C 
for 30 min. After incubation, the mixture was chilled, treated with 2 ml of phosphoric 
acid (1M), centrifuged at 15,000 rpm for 10 min, and the content of solubilized GSH 
detennined. 
GSH content was determined by HPLC with electrochemical detection. 
Chromatography was performed on a Waters HPLC system (Waters Assoc., Milford, 
MA) consisting of a Model 6000A pump, a Rheodyne injector (10 Jllioop) and a 3.9 x 
150 mm Waters Nova Pak C8 column. GSH was eluted with 8% methanol in 50 mM 
potassium phosphate buffer (pH 2.4) containing 5 mM heptane sulfonic acid with a flow 
rate of 1.2 mllmin and detected on a Bioanalytical Systems (West Lafayette, IN) LC-4B 
electrochemical detector equipped with a AulHg amalgam electrode operating at +100 V. 
The amount of sulfhydryl present in the samples was determined by comparison of peak 
heights to standards prepared identically to the samples. 
Morphological Examination of Red Cells 
After incubation, red cells treated with the vehicle (DMSO) or MAQ-NOH were 
washed and prepared for scanning electron microscopy as previously described 
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(Grossman et aI., 1992). The red cells (1 ml aliquots) were fixed in 0.1 M cacodylate 
buffer containing 1 % glutaraldehyde and 2% formalin for 20 min. The cells were affixed' 
onto O.2-JLm filters using a Swinney connector attached to a syringe. The cells were fixed 
an additional 40 min as above, washed in saline, and dehydrated in a graded series of 
ethanol solutions ranging from 50-100% ethanoL The cells were then dried by critical 
point drying, cast with a thin coat of carbon and gold, and examined in a JEOL JSM-
5410LV scanning electron microscope operating at 10 kV accelerating voltage and no 
tilt. 
Preperation of Red Cell Ghosts 
Red cell ghosts were prepared from vehicle- and MAQ-NOH-treated red cells as 
described previously (Grossman et aI., 1992). After incubation, washed red cells w'ere 
lysed in 20 ml of phosphate buffer (5 mM, pH 8.0) containing 20 mg of 
phenylmethylsulfonylfluride and centrifuged at 13,500 rpm for 10 min. The supernatant 
was removed by aspiration. The ghosts were washed extensively in phosphate buffer (3-4 
washes) to remove any unbound hemoglobin. Red cell ghosts were also prepared from 
red cells treated with dapsone hydroxylamine (DDS-NOH), and were used as a positive 
control for the presence of hemoglobin-skeletal protein adducts (Grossman et aI., 1992). 
Detennination of Lipid Peroxidation in Red Cells 
Red cells were analyzed for thiobarbituric acid-reactive substances (TBARS) as 
previously described (McMillan et aI., 1998). Following a 60 min incubation in the 
presence of MAQ:NOH, aliquots (900 JlI) of the suspension were added to 76.5 JLI of 
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trichloroacetic acid to precipitate ~he proteins and centrifuged at 13,000 x g for 2 nUn. 
The supernatants (600 pJ) were incubated with thiobarbituric acid (600 pJ 0.67% in 
water) at 100°C for 15 min. After the samples cooled to room temperature, their 
absorbance was read at 532 nm. TBARS was quantitated based on a standard cu~ve 
generated with known amounts of malondialdehyde prepared identically to the samples. 
Statistical significance was determined with the use of the Student's T -test. 
Lipid peroxidation was also ~ssessed by measuring the level of F2-isoprostanes in red 
cell ghosts prepared from MAQ-NOH-treated red cells as described previously (Morrow 
and Roberts, 1999). Membrane phospholipids were extracted from the red cell ghosts and 
subjected to alkaline hydrolysis to release esterified F2-isoprostanes. Free F2-isoprostanes 
were converted to pentafluorobenzyl ester trimethylsilylether derivatives and measured 
by GCIMS. F2-isoprostanes were quantitated based on a standard curve generated with 
known amounts of the F2-isoprostane eH4]8-iso-PGF2a• 
Electrophoretic Analysis of Membrane Skeletal Proteins 
Red cell ghosts (100 JLI) were solubilized in 40.6 JLI solubilization buffer (7% SDS, 
35% glycerol, 25 mM EDTA, 0.28 M Tris-base). Aliquots (containing 35 JLg of protein) 
were resolved on non-reducing, continuous gels consisting of 5% monomer and 1.5% bis-
acrylamide crossli,nker as described by McMillan et. aI.. (McMillan et aI., 1995). The 
resolved proteins were either stained with Gel Code Blue (Pierce,' Rockford, IL) or 
transferred to PVDF membranes according to the method of Towbin et. al. (Towbin et 
aI., 1979). The skeletal proteins were resolved Protein bands were identified according to 
their migration distance (Fairbanks et aI., 1971). 
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Blotted proteins were blocked in TBST (Tris-buffered saline containing 0.5% Tween-
20, pH 7.5) containing 5% w/v non-fat dry milk at 27°C overnight, washed 3 times,in 
TBST and incubated in TBST containing 0.1 % bovin serum albumin (fraction V) and 
primary antibody (diluted 1:10,000) at room temperature for 1 hr. The blotted proteins 
were washed 3 times in TBST containing 5% w/v non-fat dry milk and incubated with 
the peroxidase-conjugated secondary antibody at room temperature for 1 hr. Blots were 
developed with EeL detection system (Amersham Phannacia Biotech, Piscataway, NJ). 
GSH Depletion of Red Cell Suspensions 
DEM dissolved in acetone was added to packed red cells at an initial concentration of 
0.121 ttl/ml packed cells. After a 15 min incubation at 37°C the red cells were analyzed 
for aSH content by HPLC with electrochemical detection as described above. This 
treatment typically reduced aSH concentrations to about 5-10% of the initial level, and 
this level of depletion was maintained throughout the course of the experiment. The cells 
were then resuspended in PBSG (40% suspension) and used on the same day that they 
were collected. 
Detennination afthe Hemolytic Response 
The survival of 51er-Iabeled red cells in vivo after in vitro exposure to MAQ-NO'H 
was determined as described previously (Harrison and Jollow, 1986). After the 
incubation, the red cells were washed, resuspended (40% hematocrit), and an aliquot (0.5 
ml) was administered i.v. to isologous rats. To blood salnples were taken from the orbital 
sinus 30 min after the administration of the labeled cells. Additional samples were taken 
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in 48 hr intervals for 14 days. At the end of the experiment the samples were counted in a 
well-type gamma counter, and the data were expressed as a percentage of the TO blood 
sample. Each data point represents four rats. 
Results 
Effect of MAQ-NOH on Rat Erythrocyte Sulfhydryl Status 
It has been shown that GSH levels are decreased in G6PD-deficient individuals given 
primaquine (Tarlov et aI., 1962; Beutler, 1969). Thus, the effect MAQ-NOH on GSH 
levels was examined in rat erythrocytes in vitro under previously established hemolytic 
conditions (Bolchoz et aI., 2001). MAQ-NOH was added to rat red cell suspensions, and 
aliquots were taken at various time points and analyzed for aSH, ossa and OS-protein 
mixed disulfides by HPLC .. As shown in fig. 3.1A, addition of a TCso concentration of 
MAQ-NOH (350 JlM) to rat red cells resulted in a transient decline of aSH to about 70% 
of initial levels, reaching a nadir within 30 min. The loss of aSH was matched by an 
increase in both OSSG and OS-protein mixed disulfides. 
Examination of the concentration dependence of the effect of MAQ-NOH on 
erythrocyte GSH levels indicated that the pattern of the response was unchanged over the 
range of 350-1000 J,tM. When the nadir of aSH content (at 30 min) was plotted against 
MAQ-NOH concentration (fig. 3.1B), the ECso of GSH depletion by MAQ-NOH was 
estimated to be about 1000 JLM. Of interest, this concentration-response curve for MAQ-
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Fig. 3.1. (A) Effect of MAQ-NOH on rat erythrocyte sulfhydryl status. Rat erythrocytes 
were incubated at 37°C in PBSG containing MAQ-NOH (350 11M). At the indicated time 
points aliquots were withdrawn and assayed for GSH, GSSG, and GS-protein mixed 
disulfides. The values shown are means + SD (n=3). (B) Concentration response 
relationship for GSH oxidation by MAQ-NOH in rat erythrocytes. Percent reduction in 
GSH was detennined using the nadir values (30 min) for GSH as compared to controls. 
Values are means of duplicate determinations. 
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response curve previously reported for MAQ-NOH hemolytic activity (TC50 ca. 350 JLM) 
(Bolchoz et aI., 2001). 
Effect of MAQ-NOH on Rat Erythrocyte Membrane Lipids 
To determine whether lipid peroxidation could be detected in rat red cell suspensions 
exposed to MAQ-NOH, TBARS formation was measured after a 60 min incubation with 
MAQ-NOH. As shown in fig. 3.2A, the amount of TBARS formed in MAQ-NOH-treated 
red cells was increased significantly as compared to the vehicle-treated control cells. 
TBARS formation was dependent on MAQ-NOH concentration up to 350 p,M. 
Although TBARS is a widely accepted method for the measurement of lipid 
peroxidation, problems with the specificity of this assay are well known (Moore and 
Roberts, 1998). Thus, F2-isoprostane content in MAQ-NOH-treated red cell ghosts was 
used to confirm the induction of lipid peroxidation. Following a 2-hr incubation with 
various concentrations of MAQ-NOH, the cells were washed and lysed in hypotonic 
saline to prepare red cell ghosts. Esterified isoprostanes were hydrolyzed and extracted, 
and the content of free F2-isoprostanes in the sample was quantified by GC/MS. As 
shown in fig. 3.2B, MAQ-NOH induced a concentration-dependent increase in the 
formation of F2-isoprostanes, which confirmed the results obtained with the TBARS 
assay. 
Effect of MAQ-NOH on Rat Erythrocyte Membrane Skeletal Proteins 
Membrane skeletal proteins from control, DDS-NOH (included as a positive control) 
and MAQ-NOH-treated red cells were separated on SDS-PAGE gels and either stained 
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Fig. 3.2. (A) Formation of TBARS in rat erythrocytes exposed in vitro to MAQ-NOH. 
Rat erythrocytes were incubated at 37°C for 60 min in PBSG containing the indicated 
concentrations of .MAQ-NOH. Control cells were incubated in PBSG containing the 
vehicle (10 JLI DMSO). After the incubation, the cells were lysed, centrifuged and 
analyzed for TBARS as described in "Materials and Methods". The values are means + 
SD (p< 0.05, n=5). (BY Formation of F2-isoprostanes in ghosts prepared from rat 
erythrocytes exposed in vitro to MAQ-NOH. Erythrocyte suspensions (40% RCT) were 
incubated with the indicated concentrations of MAQ-NOH for 2 hrs at 37°C. After 
incubation, erythrocyte ghosts were prepared and analyzed for F2-isoprostane content as 
described in "Materials and Methods". The values are means + SD (n=4). *Significantly 
different from control (p< 0.05). 
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with Gel Code Blue or transferred to PVDF membranes and immunostained with anti-
hemoglobin polyclonal antibodies. As shown in fig. 3.3A, the electrophoretic pattern of 
membrane skeletal proteins of the positive control (DDS-NOH, lanes 6-7) showed the 
characteristic changes previously described (Grossman et aI., 1992); viz., broadening of . 
protein bands 1 and 2, loss of bands 2.1 and 4.2, splitting of band 3, and the formation of 
hemoglobin aggregates. Immunoblot analysis using the anti-hemoglobin antibody (fig. 
3.3B) confirmed that the changes in electrophoretic mobility were due to formation of 
hemoglobin adducts with the skeletal proteins, and of the presence of monomeric and 
polymeric forms of hemoglobin. 
MAQ-NOH-treated red cells (fig. 3.3A, lanes 2-5) were not significantly different 
from the control (lane 1) in regard to the mobility of the skeletal proteins. The absence of 
significant levels of skeletal protein-hemoglobin adducts was confirmed by the anti-
hemoglobin immunoblot (fig. 3.3B, lanes 2-5). Of interest, a concentration-dependent 
increase in the amount of hemoglobin monomer (16 kDa) was observed in the Gel Code 
Blue-stained gel, as well as in the anti-hemoglobin immunoblot (fig. 3.3B, lanes 2-5). 
Effect of MAQ-NOH on Rat Erythrocyte Morphology 
To investigate the effect of MAQ-NOH on rat erythrocyte morphology, red cell 
suspensions were incubated in the presence and absence of MAQ-NOH, and aliquots of 
the cells were prepared for scanning electron microscopy. As shown in fig. 3.4A, red 
cells treated with the vehicle (10 JLI DMSO in 2 ml red cell suspension) for 2 hr at 37°C 
retained their nonnal biconcave appearance, though occasional small protuberances were 
observed in some of the cells. These protuberances were not seen in cells incubated in 
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Fig. 3.3. Effect of MAQ-NOH on rat erythrocyte membrane skeletal proteins. Rat 
erythrocytes were incubated for 2 hr at 37·C in the presence of the vehicle (lane 1), 150 
JlM (lane 2), 350 tLM (lane 3), 750 tLM (lane 4), and 1.0 mM (lane 5) MAQ-NOH and 
130 JlM (lane 6) and 250 tLM (lane 7) DDS-NOH. The cells were washed and membrane 
ghost were prepared and washed extensively to remove the unbound hemoglobin. The 
ghosts (32 tLg protein) were the solubilized in SDS and subjected to PAGE. A) Gel Code 
blue stained gel and densitometric scans; B) immunoblot stained with rabbit anti-rat 




Fig. 3.4. Effect of MAQ-NOH on rat erythrocyte morphology. Scanning electron 
micrograph of (A) rat erythrocytes incubated for 2 hrs at 37°C in PBSG containing the 
vehicle; and (B) rat erythrocytes exposed to MAQ-NOH (lmM). Magnification X2000., 
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normal saline alone and are attributed to the DMSO. Rat erythrocytes incubated with 
MAQ-NOH, even at a very high concentration (1 mM; fig. 3.4B), also exhibited normal 
discocytic morphology. 
Effect of MAQ-NOH on GSH-Depleted Erythrocytes 
The enhanced sensitivity of red cells from G6PD-deficient individuals to the 
oxidative actions of certain drugs is considered to be due to their diminished capacity to 
maintain sufficient levels of NADPH, and hence GSH, when challenged by the oxidant 
stress. In an effort to reproduce this enhanced sensitivity in normal rat red cells, GSH was 
depleted by >90% using DEM prior to MAQ-NOH exposure. As shown in fig. 3.5, the 
hemolytic activity of MAQ-NOH (250 JLM) was increased markedly in GSH-deficient 
red cells (T50 = 0.85 ± ,0.06 days) as compared to MAQ-NOH-treated red cells with 
normal GSH levels (T50 = 7.4 ± 0.6 days). Survival of red cells treated with DEM alone 
(T50 = 8.6 ± 0.8 days) was not significantly different from the controls (Tso = 9.5 + 0.9 
days). As shown in Table 3.1, GSH depletion did not increase the extent of lipid 
peroxidation (TBARS formation) in MAQ-NOH treated red cells, indicating that the 
enhanced toxicity was not due to exacerbation of lipid peroxidation. 
SDS-PAGE analysis of the skeletal proteins (fig. 3.6A) revealed an increase in 
hemoglobin monomer present in aSH-deficient red cells treated with MAQ-NOH (lanes 
2-4) as compared to the GSH-norrnal MAQ-NOH control (lane 1). Immunoblot analysis 
using an anti-hemoglobin antibody (fig. 3.6B) showed that in the GSH-depleted cells, 
MAQ-NOH also caused a concentration-dependent increase in the formation of 
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Fig. 3.5. The survival of GSH depleted 51Cr-Iabeled erythrocytes in vivo after in vitro: 
exposure of 250 JlM MAQ-NOH. Radiolabeled red cells were treated with DEM to 
depleted intracellular aSH (>90%). The cells were then incubated with vehicle or 250 
JlM MAQ-NOH for 2 hr at 37°C. The erythrocytes were then washed and administered 
i. v. into a group of isologous rats. To blood samples were taken 30 min after 
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Fig. 3.6. Effect of MAQ-NOH on the membrane skeletal proteins of GSH-depleted 
erythrocytes. GSH depleted (90%) nit erythrocytes were incubated in the presence of 
DMSO (lane 1), 150JlM MAQ-NOH (lane 2), 250jlM MAQ-NOH (lane 3), or 350JLM 
MAQ-NOH (lane 4) for 2 hr at 37°C. Following exposure, the cells were washed and 
membrane ghosts were prepared and washed extensively to remove any unbound 
hemoglobin. The ghosts (32Jlg of protein) were solubilized in SDS and subjected to 
PAGE. A) Gel Code Blue stained gel B) immunoblot stained with rabbit anti-rat 
hemoglobin. The proteins were identified according to Fairbanks et al. (1971). 
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4.2). The increase in membrane-bound hemoglobin was observed in the form of high 
molecular weight aggregates (> 1 00 kDa) and in hemoglobin monomers and dimers (lanes 
2-4). These data indicate that in aSH-deficient red cells, skeletal protein becomes a 
preferential target of the oxidant action induced by MAQ-NOH. 
Discussion 
The present results demonstrate that under in vitro incubation conditions known to 
commit rat erythrocytes to premature removal from the circulation after their re-
administration to isologous animals, MAQ-NOH induced alterations in red cell 
sulfhydryl status (fig. 3.1) and caused damage to the plasma membrane in the form of 
lipid peroxidation (fig. 3.2). Overall, the data presented here support the concept that 
oxidative stress underlies MAQ-NOH hemolytic activity. 
On the one hand, the ability of MAQ-NOH to deplete GSH was not unexpected in 
view of our previous studies with other arylhydroxylamines, and as with these other 
agents, the loss of GSH could be accounted for by oxidation to GSSG and as-protein. 
However, examination of the time-course (fig. 3.1A) and concentration dependence (fig. 
3.1B) for MAQ-NOH-induced alterations in sulfhydryl status indicated that there are 
striking differences between this compound and previously examined N-hydroxy 
compounds. For example, with DDS-NOH, hemolytic activity is associated with a rapid, 
extensive and long-lasting depletion of red cell aSH (Grossman et aI., 1992). In the case 
of MAQ-NOH, the loss of aSH was transient and relatively modest across the full range 
of hemolytic concentrations. These data indicate that the MAQ-NOH concentration-
response curve for GSH oxidation (ECso ca. 1000 JlM) is well to the right of the curve 
for the hemolytic response, which has a TCso of about 350 JlM and exhibits a maximal 
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response at about 750 JLM (Bolchoz et aI., 2001). This relationship suggests that while 
MAQ-NOH does cause depletion of red cell aSH, the depletion of cellular aSH per se is 
not a prerequisite for the oxidative stress-mediated hemolytic damage that MAQ-NOH 
inflicts on the red cell. 
On the other hand, MAQ-NOH-induced lipid peroxidation was unexpected in view of 
the lack of lipid peroxidation observed previously in red cells treated with hemolytic 
concentrations of DDS-NOH (McMillan et aI., 1998). Lipid peroxidation was detected in 
MAQ-NOH-treated red cells using two independent measurements, TBARS and F2-
isoprostanes (fig. 3.2), and occurred across the range of hemolytic concentrations of 
MAQ-NOH. In contrast,. cytoskeletal protein thiol oxidation, as indicated by formation of 
hemoglobin-skeletal protein adducts, was not significant after exposure of red cells to 
hemolytic concentrations of MAQ-NOH (fig. 3.3). These data suggested that skeletal 
protein is not the preferred intracellular target of MAQ-NOH, as it is for DDS-NOH. 
It should be noted that although skeletal protein was apparently not affected by 
MAQ-NOH, there was a concentration-dependent increase in the amount of hemoglobin 
monomer present in membrane ghosts prepared from MAQ-NOH-treated red cells (fig. 
3.3). This monomer could not be removed from the ghosts by repetitive washing and is 
presumed to be bound either non-covalently (hydrophobic interaction) or covalently to 
the lipid matrix. The molecular form of this membrane-bound hemoglobin and its 
significance remain to be determined. Nevertheless, binding of the monomer may be a 
key event in the hemolytic process because it is observed with other arylhydroxylamines, 
such as DDS-NOH (Grossman et aI., 1992), and has been seen with other hemolytic 
agents, such as divicine (McMillan et aI., 2001), as well as in rat red cells aged to 
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senescence by the serial hypertransfusion technique (McMillan and Jollow, unpublished 
observations ). 
Alterations in erythrocyte morphology were notably absent in MAQ-NOH treated red 
cells (fig. 3.4). In view of the well known role of the skeletal protein assembly in the 
maintenance of red cell shape (Marchesi, 1985), the lack of gross morphological changes 
in these red cells is consistent with the absence of changes in the electrophoretic mobility 
of the skeletal proteins on SDS-PAGE gels (figs. 3.3 and 3.6). The lack of morphological 
change after hemolytic concentrations of MAQ-NOH is in sharp contrast to the dramatic 
changes in erythrocyte morphology observed with other hemolytic agents. For example, 
hemolytic concentrations of DDS-NOH and divicine induce distinctive echinocytic 
morphology (Grossman et aI., 1992; McMillan et aI., 2001), and phenylhydrazine is well 
known to cause transformation of red cells to spheroechinocytes (Rifkind and Danon, 
1965). 
Although the data presented here support an oxidative stress-type mechanism for 
MAQ-NOH hemotoxicity, its low potency as a GSH-depleting agent made us wonder 
whether cells lacking GSH (or the ability to replenish it) would be more sensitive to 
MAQ-NOH induced oxidant damage. Furthermore, we reasoned that since lipid 
peroxidation appeared causal in the hemolytic process whereas protein oxidation was not, 
then any enhancement in hemotoxicity provoked by depletion of GSH should be . 
accompanied by corresponding increases in lipid peroxidation without affecting the level 
of protein oxidation. When red cell GSH was depleted (>90%) by titration with DEM 
prior to exposure to MAQ-NOH, the hemolytic activity of MAQ-NOH was markedly 
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enhanced (fig. 3.5). Surprisingly, however, exacerbation of hemolytic activity was not 
accompanied by an increase in lipid peroxidation (Table 3.1). 
Although the SDS-PAGE pattern of the skeletal proteins was not visibly changed in 
MAQ-NOH-treated, GSH-deficient red cells (fig. 3.6A), examination of the skeletal 
proteins by immunoblotting revealed the presence of hemoglobin-skeletal protein 
adducts. Moreover, the presence of these adducts in GSH-deficient red cells was 
dependent on MAQ-NOH concentration (fig. 3.6B). The fact that the amount of 
hemoglobin adducted to the skeletal protein was insufficient to perturb the SDS-PAGE 
pattern suggests that it is quantitatively much less than that seen with equally hemotoxic 
concentrations of a "pure" protein thiol oxidizer, such as DDS-NOH. This raises the 
possibility that protein oxidation and lipid peroxidation act additively, and perhaps even 
synergistically, in initia~ing the intracellular events that lead to premature splenic 
sequestration. However, it should be noted that the quantitative relationship between the 
initial "hit" and commitment of the cells to removal is not yet known. The possibility that 
MAQ-NOH may operate by multiple mechanisms in the aSH-depleted red cell, and that 
these mechanisms may be synergistic, is intriguing and warrants further investigation. 
We have shown previously that N-hydroxylamines are responsible for the hemolytic 
acti vity observed after administration of several arylamine drugs and environmental 
chemicals, including aniline (Harrison and J ollow, 1986), dapsone (Grossman and 
Jollow, 1988), phenacetin (Jensen and JoBow, 1991) and propanil (McMillan et aI., 
1991). Although the mechanism by which these N-hydroxylamines cause hemolytic 
injury is not completely understood, evidence suggests that these compounds produce 
damage within red cells as a consequence of their coupled oxidation with 
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oxyhemoglobin, yielding methemoglobin and the arylnitroso derivative. In the course of 
this reaction, reactive oxygen species, thiyl radicals and possibly other (i.e., compound-
centered) free radicals are generated (Kiese, 1974; Maples et aI., 1990; Bradshaw et aI., 
1997). It is believed that these free radicals oxidize critical sites within the red cell that 
ultimately transmit a signal to the external cell surface, marking the cell for removal from 
circulation by macrophages. The precise internal lesion responsible for premature 
sequestration of these cells, whether on lipid or protein, is still not known. 
One theory is that free radical induced membrane lipid peroxidation may playa role 
in transmitting a signal for removal. Jain et al. (Jain, 1984) have shown that the lipid 
peroxidation byproduct malondialdehyde can flip phosphatidyl serine from the inner to 
the outer leaflet of the plasma membrane. Disruption of the asymmetrical distribution of 
phosphatidyl serine in the plasma membrane has been shown to stimulate 
erythrophagocytosis (Tanaka and Schroit, 1983; McEvoy et aI., 1986; Bonomini et aI., 
2001). A second postulate suggests that disulfide-linked hemoglobin adducts to critical 
membrane skeletal proteins, formed via hemoglobin thiyl radical attack of the protein 
free sulfhydryl groups, initiates red cell sequestration (Jollow et aI., 1995; Jollow and 
McMillan, 1998). In support of this postulate, a number of investigators have shown that 
hemoglobin attachment to the cytosolic domain of band 3 causes alterations in the lateral 
distribution of this integral membrane protein leading to the binding of autologous 
antibodies on the external cell surface, which initiates erythrophagocytosis (Lutz et aI., 
1984; Waugh et aI., 1986; Waugh et aI., 1987; Turrini et aI., 1991). 
In conclusion, assessment of the contribution that MAQ-NOH makes towards the 
hemotoxicity of primaquine is difficult. One problem is the multiplicity of unstable, 
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redox-active metabolites that are formed during the metabolic clearance of primaquine. 
These include several phenolic derivatives that have been implicated by others in the 
hemotoxicity of primaquine (Link et aI., 1985; Augusto et aI., 1988; Fletcher et aI., 1988; 
Agarwal et aI., 1991). Thus, it is conceivable that primaquine hemotoxicity in humans is 
mediated by more than one type of toxic metabolite. 
Secondly, there may be interactions among these metabolites which facilitate the 
development of oxidative damage within the erythrocyte. For example, preliminary 
observations in our laboratory indicate that a phenolic metabolite, 5-hydroxyprimaquine, 
is also a direct-acting hemolytic agent. Furthermore, in contrast to MAQ-NOH, 5-
hydroxyprimaquine is also a potent GSH-depleting agent (McMillan et aI., unpublished 
studies). This observation suggests that by depleting GSH, 5-hydroxyprimaquine may 
sensitize the red cell to the hemolytic activity of MAQ-NOH. If so, this effect would be 
amplified in G6PD-deficient red cells due to their already reduced levels of aSH. As 
noted by Degowin et al. (Degowin et aI., 1966), G6PD-deficient individuals are about 20-
30 fold more sensitive to the hemolytic activity of primaquine than are G6PD-normal 
individuals. Clearly, the possibility of metabolite synergism in primaquine-induced 
hemolytic anemia warrants further investigation. 
CHAPTER 4 
Primaquine-Induced Hemolytic Anemia: Formation of Free Radicals in Rat 
Erythrocytes Exposed to 6-Methoxy-8-Hydroxylaminoquinoline 
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Introduction 
Hemolytic anemia and methemoglobinemia are well recognized dose-limiting side 
effects in the therapeutic use of arylamine drugs, such as primaquine and dapsone 
(Beutler, 1969). Because these compounds are not hemotoxic when incubated with red 
cells in vitro, it has long been appreciated that metabolites are responsible for onset of the 
hemolytic response. In the cases of aniline (Harrison and Jollow, 1986), dapsone 
(Grossman and Jollow, 1988), and phenacetin (Jensen and JolIow, 1991), we have shown 
that the hemolytic metabolites are their N-hydroxy derivatives. Primaquine metabolism, 
on the other hand, is relatively more complex and the metabolites which mediate the 
hemotoxic responses have not been identified. A variety of known and putative phenolic 
metabolites of primaquine are redox-active and therefore have the potential to mediate 
primaquine hemotoxicity (Strother et aI., 1984; Baird et aI., 1986; Fletcher et aI., 1988; 
Agarwal et aI., 1991); however, direct evidence for their hemolytic activity is lacking. 
We have recently explored an alternative hypothesis; that primaquine hemotoxicity is 
mediated by an N-hydroxylated metabolite, 6 methoxy-8-aminoquinoline (MAQ-NOH). 
Although the mechanism underlying the damage and removal red cells by hemolytic 
N-hydroxylamines remains unclear, oxidative stress has long been considered to playa 
prominent role in the process (for review, see Beutler, 1971). This concept is based on the 
well-known association of hemotoxicity with oxidation of erythrocytic GSH (to GSSG 
and glutathione-protein mixed-disulfides), methemoglobin formation, and with 
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enhanced sensitivity to the hemolytic effect of these agents in individuals deficient in 
glucose-6-phosphate dehydrogenase (G6PD) activity. 
Considerable evidence generated by Kiese and colleagues (Kiese, 1974) suggests. that 
the oxidative stress provoked by N-hydroxylamines is due to a cyclic oxidation-reduction 
reaction involving the hydroxylamine, oxyhemoglobin, and molecular oxygen, to yield 
the nitrosoarene, methemoglobin, and partially reduced forms of oxygen, respectively. 
This interaction has been shown to produce greater than stoichiometric amounts, of 
reactive oxygen species (i.e., hydrogen peroxide, superoxide anion radical, hydroxyl 
radical) and sulfur-centered free radicals (i.e., glutathione and hemoglobin thiyl radicals), 
and thus has long been considered to generate reactive species capable of causing cellular 
injury (Rostorfer and . Cormier, 1957; Maples et ai., 1990; Bradshaw et aI., 1995; 
Bradshaw et aI., 1997). 
We have reported recently that an N-hydroxy metabolite of primaquine, MAQ-NOH, 
is a direct-acting hemolytic agent in rats, and hence may be a contributor to primaqui,ne-
induced hemolytic anemia (Bolchoz et aI., 2001). Although the hemolytic response 
induced by this metabolite was generally similar to that of other structurally related 
hydroxylamines, we observed some marked differences in the· oxidative activity of this 
metabolite in rat red cells (Bolchoz et aI., 2002). Of interest, when hemolytic 
concentrations of MAQ-NOH were added to rat red cells, the depletion of cellular aSH 
and the formation of methemoglobin was significantly less than that seen with equally 
hemolytic concentrations of other arylhydroxylamines, implying a quantitative difference 
in the extent of oxidant stress and cellular injury. Furthermore, this metabolite induced 
concentration dependent lipid peroxidation without evidence of protein oxidation. 
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However, when red cell aSH was depleted by titration with diethyl maleate prior to 
MAQ-NOH exposure, there was a marked enhancement of hemolytic activity without a 
corresponding increase in lipid peroxidation. The enhanced hemotoxicity was 
accompanied instead by the appearance of protein oxidation in the form of disulfide-
linked hemoglobin-skeletal protein adducts. We have hypothesized that free radicals, 
derived either from molecular oxygen or MAQ-NOH itself (i.e., a compound-centered 
free radical), are responsible for the damage to membrane lipids and skeletal proteins that 
marks the injured red cells for premature removal from the circulation by macrophages in 
the spleen. 
Thus, the present studies were conducted to determine if free radicals could be 
detected and identified in rat red cell suspensions exposed to hemolytic concentrations of 
MAQ-NOH, and thus have a role in MAQ-NOH-induced hemolytic injury. MAQ-NOH 
was added to rat red cell suspensions, and the incubates were analyzed by UV-visible 
spectroscopy and EPR using the spin trap 2-ethoxycarbonyl-2-methyl-3,4-dihydro-2H-
pyrrole-l-oxide (EMPO). We report that MAQ-NOH was able to generate hydroxyl 
radicals and ferryl heme species under hemolytic conditions. Furthermore, formation of 
the hydroxyl radical was constant for twenty minutes and dependent on the presence of 
erythrocytic aSH. These data support the concept that oxygen free radicals are involved 
in the process underlying MAQ-NOH-induced hemolytic damage 
Materials and Methods 
Chemicals 
89 
Diethylenetriaminepentaacetic acid (DTPA) and diethyl maleate were obtained from 
Sigma Chemical Co. (St. Louis, MO). EMPO was purchased from Oxis Research. 
(Portland OR). MAQ-NOH was synthesized as described previously (Allahyari et aI., 
1984). All other reagents were of the best commercially available grade. 
Animals 
Male Sprague-Dawley rats were purchased from Harlan Labs (Indianapolis, IN) and 
were maintained on food and water ad libitum. Animals were acclimated to a 12-hour 
light-dark cycle for one week prior to their use. Blood was collected from the descending 
aorta of anesthetized rats into heparinized tubes and washed three times in isotonic 
phosphate-buffered saline (pH 7.4) supplemented with 10 mM D-glucose (PBSG). 
Following removal of th~ plasma and buffy coat, the cells were resuspended (40% 
hematocrit) and used the same day they were collected. 
EPR studies 
Reaction mixtures (2 ml) contained 10 mM EMPO, 0.1 mM DTPA in a red cell 
suspension (40%) in PBSG at room temperature under aerobic conditions. Experiments 
that utilized hemolyzed red cells were conducted by suspending wased red cells in ice-
cold de-ionized water. Reactions were initiated by addition of MAQ-NOH dissolved in 
DMSO (10 ttl). EPR spectra were recorded on a Bruker ELEXYS E-500-10/12 
spectrometer system (Bruker Instruments, Inc., Billerica, MA) operating at 20 mW power 
with a microwave frequency of 9.77 GHz, a receiver gain of 69, and a time constant of 
0.164 sec. 
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Stability of MAQ-NOH in buffer and in red cell suspensions was determined by 
HPLC with electrochemical detection as described previously (Bolchoz et aI., 2001). For 
experiments to determine the dependence of radical adduct generation on red cell GSH, 
red cell suspensions were titrated with diethyl maleate to deplete aSH (by >95%) as 
described previously (Bolchoz et aI., 2002). 
Spectrophotometric detection of hemoglobin oxidation 
Fonnation of methemoglobin was determined as described previously (Harrison and 
Jollow, 1987; Bradshaw et aI., 1997). To determined if MAQ-NOH induced 
ferrylhemoglobin formation in rat red cells (Harrison and Jollow, 1987; Bradshaw et aI., 
1997), aliquots (75 JlI) of MAQ-NOH-treated red cell suspensions were lysed in 5 ml of 
hemolysis buffer (5 mM sodium phosphate dibasic, 0.5% triton X-laO, pH 7.5) and 
analyzed in a Shimadzu UV-160A double-beam UV-visible spectrophotometer. The 
amount of ferrylhemoglobin was measured in red cell incubates treated with sodium 
sulfide (2 mM) at 37°C for 5 min prior to MAQ-NOH exposure. Sodium sulfide 
irreversibly converts the unstable ferry I heme species to sulfhemoglobin which is 
measured spectrophotometrically at 620 nm (Giulivi and Davies, 1990). 
Results 
Fonnation of EMPO radical adducts in rat red cells 
To establish whether free radicals could be detected in rat red cells exposed to MAQ-
NOH under previously determined hemolytic conditions (Bolchoz et aI., 2001), rat red 
cell suspensions (400/0 hematocrit) containing 10. mM EMPO were exposed to 350 JIM 
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MAQ-NOH. As shown in figure 4.1, a four line (1:2:2:1) EMPO radical adduct signal 
was generated. The signal was dependent on the presence of MAQ-NOH (fig. 4.1B) and 
EMPO (fig. 4.1C), and was generated equally well in intact and lysed red cells (fig. 4.1 A 
and E). The nitrogen hyperfine splitting constants (Table 4.1) were identical to those of 
an EMPO hydroxyl radical adduct (Olive et aI., 2000). As shown in figure 4.2, formation 
of the EMPO-OH was concentration-dependent, and occurred over a range of hemolytic 
concentrations of MAQ-NOH. No evidence for an EMPO-thiyl radical adduct or a 
compound-centered free radical was observed in these incubates. 
Time dependence of hydroxyl radical fonnation 
Previous EPR studies using the spin trap, 5,5-dimethyl-pyrroline N-oxide (DMPO), 
have demonstrated that glutathione thiyl radical adducts are generated in rat red cell 
suspensions exposed to hemolytic concentrations of the arylhydroxylamine, 
phenylhydroxylamine (Maples et aI., 1990; Bradshaw et aI., 1995). These experiments 
also revealed that at higher drug concentrations and longer incubation times, the 
glutathione thiyl radical adduct signal was replaced by a hemoglobin thiyl radical adduct 
signal. In the present study, when rat red cells containing EMPO were exposed to MAQ-
NOH (350 JlM) and the spectrum recorded for 30 min, no change in the shape of the 
hydroxyl radical signal was detected (fig. 4.3). However, the signal intensity began to 
decline after 20 min., due to decay. 
To investigate whether the production of the hydroxyl radical was constant with time, 






Fig. 4.1. Detection of EMPO-radical adduct signal in rat erythrocytes exposed to MAQ-
NOH. (A) EPR spectrum recorded 3 min after the addition of MAQ-NOH (350 /lM) to a 
40% red cell suspension in PBSG containing 10 mM EMPO and 0.1 mM DTPA. (B) As 
in A, except MAQ-NOH was omitted .. (C) As in A, except EMPO was omitted. CD) As in 
A, except red cells were omitted. (E) As in A, except lysed red cells were used. 
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Table 4.1. Hyperfine splitting constants of EMPO Hydroxyl Adduct Diastereomers 
Spin Adduct 
EMPO-OHa 14.0 15.1 0.9 
14.0 12.7 
EMPO-OHb 13.94 14.97 0.73 
14.06 12.88 
aFrom Olive, 2000 







Fig. 4.2. Concentration-dependent increase in the MAQ-NOH-induced EMPO-OH signal 
in rat erythrocytes. EPR spectrum recorded 3 min after the addition of (A) 150 JlM, (B) 
350, (C) 750 JlM, or (D) 1.5 mM MAQ-NOH to 40% red cell suspension in PBSG 








Fig. 4.3. Time dependence of MAQ-NOH-induced EMPO-radical adduct signal in rat 
erythrocytes. EPR spectrum recorded (A) 1 min, (B) 3 min, (C) 6 min, (D) 10 min, (E) 15 
min, and (F) 30 min after the addition of MAQ-NOH (350 JLM) to 40% red cell 








Fig. 4.4. Effect of time of EMPO addition on the MAQ-NOH-induced EPR signal. 10-
mM EMPO was added to a 40% red cell suspension in PBSG containing 0.1 mM DTPA 
(A) 1 min, (B) 5 min, (C) 10 min, (D) 20 min, (E) 30 min after the addition of MAQ·-
NOH (350 JlM). EPR spectrum recorded 3 min after the addition EMPO. 
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the mixture after 1, 5, 10, 20, and 30 min. As seen in figure 4.4, the hydroxyl radical 
adduct intensity was independent of the time the trap was added up to 20 min, after which 
the signal intensity began to decline. 
To determine the relative stability of MAQ-NOH in buffer (PBSG) vs. red cells, the 
concentration of MAQ-NOH was measured in aliquots of the incubates by HPLC-EC. In 
the presence of red cells at 37°C, MAQ-NOH was highly unstable and with a half-life of 
about 2 min (data not shown). In contrast, when incubated in buffer alone, MAQ-NOH 
was relatively stable, disappearing with a half-life of about 4 min. 
Effect ofGSH depletion on hydroxyl radicalfonnation 
Recent work in this laboratory has shown that MAQ-NOH hemolytic activity is 
markedly enhanced in rat red cells depleted of reduced glutathione (>90%) (Bolchoz et 
aI., 2002). To examine the effect of aSH depletion on hydroxyl radical fonnation, rat red 
cells were depleted of GSH (>95%) by titration with diethyl maleate prior to their 
exposure to MAQ-NOH. As shown in figure 4.5, hydroxyl radical adducts were not 
detected in suspensions that lacked GSH, even using concentrations of MAQ-NOH as 
high as 750 JlM. 
Ferrylhemoglobinfonnation in rat red cells 
Ferrylhemoglobin is known to be generated in red cells by the interaction of 
oxyhemoglobin and H202, and is considered to be a potent cytotoxic oxidant capable of 
peroxidation of unsaturated fatty acids (Kanner and Harel, 1985b; Kanner and Harel, 






Fig. 4.5. Effect of removal of GSH from rat erythrocytes on the MAQ-NOH generated 
EPR signal. (A) EPR spectrum recorded 3 min after the addition of 150 JlM MAQ-NOH 
to 40% red cell suspension in PBSG containing 10 mM EMPO and 0.1 mM DTPA. (B) 
As in A, except red cells were treated with DEM to deplete aSH (>95%). (C) As in A, 
except 750 J.LM MAQ-NOH was added. (D) As in C, except red cells were treated with 
DEM to deplete GSH (>95%). 
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peroxidation in rat red cells (Bolchoz et aI., 2002), it was of interest to determine if 
ferrylhemoglobin was formed under the conditions used to detect free radical generation 
by EPR. Spectrophotometric scans of rat red cells exposed to hemolytic concentrations of 
MAQ-NOH (fig. 4.6) did not reveal the presence of ferrylhemoglobin as measured by 
increased absorbance at 545 and 580 nm. However, when the rat red cells were pretreated 
with Na2S to trap ferryl heme species as sulfuemoglobin (Berzofsky et aI., 1971), the 
presence of ferrylhemoglobin could be demonstrated. The fact that ferrylhemoglobin was 
detectable only by accumulation of sulfhemoglobin suggests a steady low level 
production of this oxidant species during the incubation period. Production of ferry! heme 
was dependent on MAQ-NOH ~oncentration (fig. 4.7 A) and on incubation time (fig. 
4.7B). 
Effect ofGSH depletion onferrylheme and methemoglobinfonnation 
Since the enhancement of MAQ-NOH hemolytic activity caused by depletion of 
cellular GSH was accompanied by loss of the hydroxyl radical signal, it was of interest to 
determine if the enhanced toxicity was accompanied by ferrylhemoglobin formation. 
GSH-normal and GSH-depleted rat red cells were treated with a range of hemolytic 
concentrations of MAQ-NOH and assayed for ferrylhemoglobin. As shown in figure 
4.8A, depletion of cellular GSH prior to addition of MAQ-NOH had no effect of the 
formation of ferryl heme in the red cells. Since ferrylhemoglobin is known to undergo a 
comproportionation reaction with oxyhemoglobin to yield molecules of methemoglobin 
(Giulivi and Davies, 1990), we also examined the effect of aSH depletion and of Na2S 




















Fig. 4.6. Spectrophotometric detection of ferrylhemoglobin in rat erythrocytes exposed to 
MAQ-NOH. Rat erythrocytes (40% suspension) were pre-incubated with sodium sulfide 
(2 mM) to convert the ferryl heme species to sulfhemoglobin (Amax 620 nm) and then 
exposed to 750 ILM MAQ-NOH for 30 min at 37°C. 10% Potassium cyanide (20 ILl) was 
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Fig. 4.7. Effect of concentration and time on MAQ-NOH-induced ferrylhemoglobin 
formation. (A) Absorbance at 620 nm 10 min after the addition of various hemolytic 
concentrations of MAQ-NOH to red cell incubates containing 2 mM sodium sulfide. 10% 
Potassium cyanide (20 Jll) was added to remove any absorbance interference due to 
methemoglobin. (B) As in A, except red cells were incubated in 350 jiM MAQ-NOH and 
aliquots taken at various time points. 
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Fig. 4.8. Effect of aSH depletion on MAQ ... NOH-induced (A) ferrylhemoglobin 
formation. Absorbance was recorded at 620 nm 10 min after the addition of various 
hemolytic concentrations of MAQ-NOH to red cell incubates containing 2 rnM sodium · 
sulfide. aSH-depleted red cells were treated with DEM prior to MAQ-NOH exposure. 
10% Potassium cyanide (20 Jll) was added to remove any absorbance interference due to 
methemoglobin. Data points are means + SD (n=6). (B) As in A, except methemoglobin 
was determined as described previously (Harrison and Jollow, 1987). Data points are 
means + SD (n=4). 
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depletion of GSH from the rat red cells also had no effect on the formation of 
methemoglobin. 
Since inclusion of Na2S in the incubation medium acts to trap ferryl heme as it is 
formed, comparison of methemoglobin levels in the presence and absence of Na2S is a 
measure of the contribution of this pathway to methemoglobin formation induced by 
MAQ-NOH. As shown in figure 4.9, methemoglobin formation was unaffected by the 
presence of Na2S, indicating that ferryl heme is not a major contributor to MAQ-NOH-
induced methemoglobin fonnation. 
Discussion 
In previous studies on primaquine-induced hemolytic anemia, we demonstrated that 
its N-hydroxy metabolit.e, MAQ-NOH, is directly hemolytic in rats and that this 
hemotoxicity is associated with lipid peroxidation without significant protein oxidation 
(Bolchoz et aI., 2001, Bolchoz, 2002 #306). However, when GSH is depleted prior to 
MAQ-NOH exposure, there is a pronounced exacerbation of MAQ-NOH hemolytic 
activity, and this exacerbation is accompanied by the appearance of protein oxidation 
without change in lipid peroxidation. The present studies were undertaken to determine if 
radical species are produced in rat red cells exposed to hemolytic concentrations of 
MAQ-NOH, and if so, whether the enhancement of hemolytic activity by aSH depletion 
is accompanied by alterations in free radical formation. 
Experimentally, rat red cells were incubated with MAQ-NOH and analyzed by EPR 
using EM PO as the free radical spin trap. EMPO was utilized instead of the more widely 
used trapping agent, DMPO, because its superoxide radical adduct is more stable and 
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Fig. 4.9. Effect of Na2S pretreatment on MAQ-NOH-induced methemoglobin formation. 
Red cell suspensions were incubated with 2 mM sodium sulfide or PBSG for 5 min prior 
to the addition of MAQ-NOH (750 JLM). Methemoglobin was determined as described 
previously (Harrison and Jollow, 1987). Data points are means + SD (n=3). 
105 
does not spontaneously decay to a hydroxyl radical adduct signal (Olive et aI., 2000; 
Zhang et aI., 2000), as is observed with the DMPO-superoxide adduct (Thomalley, 1986; 
Makino et aI., 1990; Hanna et aI., 1992). We report that MAQ-NOH generated an 
EMPO-hydroxyl radical adduct (fig 4.1) that was dependent on the presence of red cells 
(intact or lysed), EMPO, and MAQ-NOH. The EMPO-hydroxyl radical adduct signal was 
stable for 20 min (fig. 4.3) and its intensity was proportional to MAQ-NOH concentration 
(fig. 4.2). Addition of the EMPO reagent at intervals after exposure of the red cells to 
MAQ-NOH (fig. 4.4) generated a radical signal at a constant intensity for at least 20 min. 
As noted above, depletion of red cell aSH prior to the addition of MAQ-NOH 
significantly enhances the hemolytic activity of MAQ-NOH. Paradoxically, hydroxyl 
radical was not only not enhanced, but was lost completely (fig. 4.5). Furthennore, the 
increased toxicity was not accompanied by an increase in ferryl heme formation (fig. 
4.8A), and, hence by implication, not by increased levels of hydrogen peroxide. 
Although a hydroxyl radical has previously been shown to be generated in red cells 
exposed to other hemolytic N-hydroxylamines, such dapsone hydroxylamine (Bradshaw 
et aI., 1997), the mechanism by which the radical is generated is unclear. It is well known 
that oxyhemoglobin exists in the red cell as an equilibrium mixture, which includes a 
superoxide-ferriheme component. Dissociation of this complex is believed to be 
responsible for the constant, low-level oxidant stress that is present in unchallenged red 
cells. Kiese and colleagues (for review, see Kiese, 1974) proposed an interaction between 
arylhydroxylamines and oxyhemoglobin that may be regarded as an exacerbation of this 
normal process. Thus, they described the occurrence of a cyclic oxidation-reduction 
reaction between arylhydroxylamines and oxyhemoglobin, that yields the nitrosoarene, 
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methemoglobin, and a reactive oxygen specIes (such as superoxide or hydrogen 
peroxide), respectively. Subsequent reduction of methemoglobin by NADH-dependent 
methemoglobin reductase, and of the nitrosoarene by a NADPH-dependent diaphorase, 
would support a greater than one-to-one stoichiometry in regard to acti ve oxygen 
production. Superoxide/hydrogen peroxide would in turn generate hydroxyl radicals by 
way of an iron-catalyzed Fenton reaction. Although there is controversy over whether 
hemoglobin is able to catalyze a Fenton reaction (Gutteridge, 1986; Puppo and Halliwell, 
1988; Dong Mao et aI., 1994), Comporti and colleagues (Ferrali et aI., 1992; Ciccoli et 
aI., 1994; Ciccoli et aI., 1999) have presented evidence to suggest that oxidation of 
hemoglobin to methemoglobin facilitates the release of heme and/or free iron in a 
diffusible, redox-active form. 
Although the MAQ-NOH-induced hydroxyl radical of the present studies could be 
generated by this mechanism, the loss of the hydroxyl radical when aSH was depleted 
from the red cells strongly suggests that GSH is involved in the process. An alternate 
hypothesis, proposed by Winterbourn and colleagues (Munday and Winterbourn, 1989; 
Winterbourn, 1993), is that superoxide formation is dependent on GSH. In this concept, 
GSH acts as a direct radical scavenger of a di verse range of radical species, accepting the 
unpaired electron from the radical to form a glutathione thiyl radical intennediate. The 
thiyl radical electron is then passed on to molecular oxygen to form superoxide anion 
radical, which under normal conditions is detoxified by superoxide dismutase, creating a 
GSHlsuperoxide radical sink. In the present studies, an excessive production of 
superoxide/hydrogen peroxide induced by the hemolytic concentration of MAQ-NOH, in 
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the presence of kinetically-free iron derived from methemoglobin, could account for the 
observed hydroxyl radical signal. 
It is apparent that while the GSHIsuperoxide radical sink concept explains 
satisfactorily the dependence of the hydroxyl radical signal on cellular aSH levels, it 
does not provide an explanation for the initiation of the radical series or how 
methemoglobin formation is provoked by MAQ-NOH. The relative stability of MAQ-
NOH in buffer (T1I2 ca. 4 min) as compared with its instability in the red cells (Tl/2 < 2 
min) suggests that a spontaneous reaction with molecular oxygen (i.e., auto-oxidation) to 
generate the initial radical species is unlikely, and that in some fashion, hemoglobin or 
other cellular constituents are needed to initiate radical formation. Similarly, comparison 
of methemoglobin levels in the presence and absence of Na2S (fig. 4.9) indicates that the 
comproportionation of ferryl heme is not a major contributor to MAQ-NOH-induced 
methemoglobin formation, and hence that methemoglobin must arise by a different 
pathway. 
While neither postulate alone provides a' satisfactory explanation, a combination 
appears to be compatible with the current data. Thus, the very rapid disappearance of 
MAQ-NOH in red cells and rapid formation of methemoglobin (Bolchoz et aI., 2001) 
suggest that the interaction of MAQ-NOH and hemoglobin could gene-rate 
methemoglobin and a compound-centered free radical, such as a quinoline hydronitroxide 
radical. The generation of this species ma~ be analogous to the formation of the 
phenylhydronitroxide radical form of phenylhydroxylamine described by Mason and: 
colleagues (Maples et aI., 1990). Once formed, the nitroxide free radical could react with 
aSH to form a thiyl radical, which in tum, could generate a superoxide radical and lead 
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to hydrogen peroxide formation vi~ superoxide dismutase (Fridovich, 1975). As noted 
above, kinetically-free iron derived from methemoglobin could catalyze hydroxyl radical 
formation. 
Although this combined schema permits rationalization of the available data, it should 
be noted that there are major discrepancies. First, we have been unable to detect a 
compound-centered radical derived from MAQ-NOH in the red cell incubates. Of 
interest, aerobic incubation of MAQ-NOH in PBSG buffer alone (without the iron 
chelator, DTPA) gives rise to a radical species that can be detected by EPR (data not 
shown). The identity of this species and its relevance to hemotoxicity are currently under 
investigation. Second, w~ have been unable to clearly detect a glutathione thiyl radical in 
MAQ-NOH incubates. This is of concern since previous analogous studies with 
phenylhyrdroxylamine demonstrated the presence of thiyl radicals (Maples et aI., 1990; 
Bradshaw et aI., 1995). However, since the EMPO-hydroxyl and EMPO-GSH thiyl 
radical adduct signals are similar, with a characteristic 1 :2:2: 1 signal pattern, simulation 
experiments are necessary to determine if this signal is present and just masked by the 
hydroxyl signal. 
A third major concern is the lack of correlation between the very rapid disappearance 
of MAQ-NOH and the apparent steady production of hydroxyl radical for at least 20 min 
after addition of the MAQ-NOH to the red cells. The fact that hydroxyl radical continues 
to be generated long after MAQ-NOH has disappeared argues strongly that MAQ-NOH 
induces the fonnation of an as yet undetected, more stable intermediate. Support for the 
existence of such a species can also be seen in MAQ-NOH-treated, GSH-depleted red 
cells. Although the hydroxyl radical can no longer be detected, addition of the lipid 
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soluble sulfhydryl-donating compound, cysteamine, leads to the trapping of a cysteamine 
thiyl radical by EMPO (Bolchoz et aI., unpublished observations). Thus even in red cells> 
in which the hydroxyl radical is not detectable, a precursor species more stable that 
MAQ-NOH must be present. 
The role of hydrogen peroxide in the hemolytic process is also unclear. It is well 
known that hydrogen peroxide reacts with hemoglobin to form ferryl heme and hence 
that ferryl heme levels in the red cells reflect the generation of hydrogen peroxide in 
excess of its metabolic clearance (Kanner and Harel, 1985b;. Kanner and Harel; 1985a; 
Harel and Kanner, 1988). Thus the formation of ferrylhemoglobin in these red cells may 
be taken as evidence for the formation of excess hydrogen peroxide under MAQ-NOH-
induced hemolytic conditions. However, it has long been thought that glutathione 
peroxidase plays a major role in the removal of hydrogen peroxide from the red cell 
(Jacob, 1965). Thus, in the present studies, depletion of GSH from the red cells should 
have decreased hydrogen peroxide elimination by glutathione peroxidase, resulting in 
enhanced hydrogen peroxide levels and enhanced ferryl heme formation. Experimentally, 
depletion of red cell GSH had no effect on the production of ferryl heme (fig. 4.8A), 
implying no significant change in hydrogen peroxide levels. Since ferryl heme appears to 
play little or no role in MAQ-NOH-induced methemoglobin formation (fig. 4.8B), the 
lack of enhancement in ferryl heme levels is not due to enhanced removal by 
comproportionation to methemoglobin. The data are consistent with the proposal by 
Eaton and colleagues (Eaton, 1991) that catalase plays a more significant role in 
controlling red cell peroxide levels than has previously been considered. 
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In summary, the present studies clearly demonstrate that under hemolytic conditions, 
MAQ-NOH generates three active oxygen species in rat red cells: hydroxyl radical, 
hydrogen peroxide and ferryl heme, each of which has the chemical potential to inflict 
the initial oxidant injury to the red cell that ultimately leads to its premature sequestration 
by the spleen. However, enhancement of the susceptibility of the cells by prior depletion 
of cellular GSH did not increase the levels of any of these species and hence these data 
alone do not allow us to conclude which, if any, of these oxidants could be causal in 
MAQ-NOH hemotoxicity. Of particular interest, the marked discrepancy between the 
rapid disappearance of MAQ-NOH from the red cell incubate and the sustained oxidant 
stress for at least 20 min suggests the presence of an, as yet, undetected pro-oxidant 





Hemolytic anemia has been recognized as a toxic side effect of a wide variety of 
drugs and environmental chemicals for more than 50 years (Cordes, 1926). While the 
precise mechanism in which these agents elicit a hemolytic response remains unclear, it is 
generally accepted that oxidative stress plays a central role. Support for the oxidative 
stress concept lies in a number of observations made in early mechanistic studies (for 
review, see Beutler, 1959). These include: 1) loss of cellular reduced glutathione 
following exposure to these agents, 2) oxidation of oxyhemoglobin to methemoglobin, 
and 3)- cells that are unable to maintain adequate levels of the reductant NADPH (i.e., 
G6PD deficient cells) when faced with an oxidative challenge are the most sensitive to 
these agents. In addition, these studies established that metabolites were responsible for 
the hemolytic activity of the parent compound. 
While the crucial role for metabolism in primaquine-induced hemolytic anemia is 
well accepted, the hemotoxic metabolite(s) have not been identified. Furthermore, the 
mechanism underlying this toxicity is not fully understood. This is in one part due to 
multiple oxidation sites on the primaquine molecule that give rise to a number of possible 
primary metabolites that may be further metabolized. Secondly, many of these putative 
metabolites are known to be chemically unstable in biological systems (Strother et aI., 
1981; Idowu et aI., 1995). In addition, investigators lack a good primaquine-sensitive 
experimental animal model (Lee et aI., 1981). 
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It has long been suggested that primaquine hemotoxicity is mediated by redox active 
phenolic metabolites of the parent compound (Tarlov et aI., 1962). These metabolites are 
believed to redox cycle within the red cell to their respective quinone/ quinoneimine 
structure resulting in the formation of reactive oxygen species (Link et aI., 1985). In 
support, 5-0H-PQ and 5,6-DHPQ have been detected in the biological fluid of 
experimental animals administered primaquine (Strotheret aI., 1981; Strother et aI., 
1984; Idowu et ai., 1995), and these metabolites have been shown to decrease 
erythrocytic GSH levels and oxidize hemoglobin to methemoglobin in both normal and 
G6PD-defecient erythrocytes (Fraser and VeseIl, 1968; Agarwal et aI., 1988; 'Fletcher et 
aI., 1988). However, these derivatives have not been detected in humans (Baty et aI., 
1975; Mihaly et aI., 1984). 
Alternatively, previous studies with hemolytic arylamines such as aniline (Harrison 
and Jollow, 1986), phenacetin (Jensen and Jollow, 1991), and dapsone (Grossman and 
Jollow, 1988), have shown that their N-hydroxy metabolites are the hemotoxic species. 
Evidence suggests that these agents evoke an oxidative stress within the red cell through 
a cyclic oxidation-reduction reaction that occurs between the arylhydroxylamine, 
oxyhemoglobin, and molecular oxygen yielding the nitrosoarene, methemoglobin, and 
partially reduced forms of oxygen, respectively (Rostorfer and Cormier, 1957; Kiese, 
1974). In support, extensive studies on the mechanism of DDS-NOR-induced hemolytic 
anemia revealed that this metabolite induced a variety of oxidative events in rat and 
human erythrocytes under hemolytic 'conditions (Grossman and Jollow, 1988; Grossman 
et aI., 1992; McMillan et aI., 1995; Bradshaw et aI., 1997). These include: 1) rapid and 
extensive depletion of GSH with a concomitant formation of GSH-protein mixed 
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disulfides, 2) formation of disulfide-linked hemoglobin adducts to certain membrane 
skeletal proteins, 3) oxidation of hemoglobin, and 4) generation of hydroxy I radicals. In 
contrast, DDS-NOH did not oxidatively damage red cell membrane lipids (McMillan et 
aI., 1998). Collecti vely, these observations led to the concept (fig. 1.5) that 
ary Ihydroxy lamines redox cycle within the red cell, generating oxygen-centered free 
radicals, which in tum form aSH and hemoglobin thiyl radicals. The hemoglobin thiyl 
radicals are believed to further react with the sulfhydryl groups of the membrane skeletal 
proteins to fonn hemoglobin-skeletal protein adducts and ultimately mark the red cell for 
premature removal by the spleen (Grossman et aI., 1992). 
In light of these studies, this dissertation examines the possible role of an N-hydroxy 
metabolite in primaquine-induced hemotoxicity. The experimental approach was to 
determine if this type of metabolite is formed metabolically, to establish its hemolytic 
acti vi ty, to characterize the pattern of oxidative damage induced in the red cell 
particularly to membrane lipids and cytoskeletal proteins and to identify the nature of the 
oxidati ve stress generated by this metabolite in the red cell. 
Fonnation and hemotoxicity o/primaquine N-hydroxy metabolite 
As 6-methoxy-8-aminoquinoline (6-MAQ) is one of two known human primaquine 
metabolites, rat and human microsomes were analyzed for their capacity to N-
hydroxylate this metabolite. As seen in figure 2.5, incubation of 6-MAQ with rat and 
human liver microsomes resulted in the formation of a single metabolite that was 
identified by mass spectrometry to be MAQ-NOH (fig. 2.7). MAQ-NOH was further 
shown to be hemolytic in vivo as measured by the decreased survival of S1er-Iabeled 
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erythrocytes in rats. Of particular interest, incubation of MAQ-NOH with 51Cr-labeled 
erythrocytes in vitro resulted in a concentration-dependent increase (ECSO 350 JiM) in 
their rate of removal when administered to a group of isologous rats. MAQ-NOH also 
induced a concentration-dependent increase in methemoglobin levels in rat red cells 
when exposed in vitro. Collectively these data suggest that the 6-MAQ can be 
metabolized to MAQ-NOH and that this metabolite has the requisite properties to playa 
role in the hemolytic activity of primaquine. However, the contribution of MAQ-NOH to 
primaquine-induced hemolytic anemia in vivo remains to be assessed. 
Hemolytic d~se-respose·relationship 
In regard to the in vitro exposure/ in vivo survival assay employed in this aim, it is 
important to note that the metabolite concentrations needed to elicit a hemolytic response 
in vitro may not be extrapolated to define the concentration of these drugs needed to elicit 
a hemolytic response in vivo. One reason for this is that the hemolytic activity of these 
agents is being tested in G6PD-normal rat erythrocytes. Since these red cells have normal 
aSH levels and can maintain NADPH levels and hence antioxidant enzyme activity when 
challenged with an oxidative stress, we must use metabolite concentrations that not only 
deplete aSH, but also generate enough oxidative stress to overwhelm the antioxidant 
enzymes in order to elicit a toxic response. 
Secondly, drug-induced hemolytic ane~ia is believed to be the result of an 
accumulation of multiple "hits" after which a threshold is reached the cells are removed 
from circulation. Thus hemolytic damage would be proportional to the area under the 
metabolite plasma concentration vs time curve and not the peak metabolite plasma levels, 
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as has been illustrated for the hemolytic metabolite of dapsone, dapsone hydroxylamine 
(Grossman and Jollow, 1988). Primaquine has a half-life of about 6 hrs (Mihaly et al., 
1984), therefore it is conceivable that 6-MAQ and MAQ-NOH will be produced at a low 
but steady rate. Since primaquine is usually administered chronically, the area under the 
MAQ-NOH plasma concentration versus time curve may be significant, particularly in a 
G6PD-deficient individuaL However, since the red cells in our survival assay are only 
exposed to the metabolites in vitro for 2 hrs, higher than physiological relevant 
concentrations of metabolites must be used. 
On the contrary, this assay does provide a method in which shorter incubation times 
can be used to determine the relative potencies of direct acting hemolytic compounds~ In 
addition, in vitro experimental conditions are established that result in the in vivo 
premature sequestration of red cells. Thus parallel studies may be conducted to examine 
the biochemical changes that occur in the red cells under these conditions and their 
possible role in marking the red cell for removal ascertained. 
Oxidative effects of MAQ-NOH in rat erythrocytes under hemolytic conditions 
Being that MAQ-NOH is an arylhydroxylamine like DDS~NOH, it was expected to 
behave in a similar nature in the red blood cell. However, in marked contrast to the DDS-
NOH, MAQ-NOH was shown to induce significant lipid peroxidation in rat erythrocytes 
with little effect on the membrane skeletal proteins under equally hemolytic conditions. 
Of particular interest, MAQ-NOH exposure resulted in hemoglobin monomer association 
with the erythrocyte lipid membrane. The monomer could not be removed despite 
multiple rigorous washes in phosphate buffer suggesting it was bound either non-
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covalently (hydrophobic interactions) or covalently to the lipid bilayer. As this monomer 
has also been seen in red cells treated with other hemolytic agents, for example DDS-
NOH, phenylhydrazine, and divicine, the nature of the monomer association with the red 
cell membrane and its possible role in marking the cell for splenic sequestration as 
apposed to or in conjunction with the cytoskeletal adducts or lipid peroxidation becomes 
of interest. 
MAQ-NOH was also shown to differ from DDS-NOH in its effects on aSH in rat red 
cells. As illustrated in figure 3.1, MAQ-NOH only moderately and transiently decreased 
aSH levels. In fact the concentration-response curve for MAQ-NOH aSH depletion is 
far to the right of its hemolytic response curve suggesting that GSH depletion is not a 
prerequisite for oxidative hemolytic damage. 
Oxidative effects of MAQ-NOH in GSH-depleted rat erythrocytes 
In an effort to investigate the oxidative effects of MAQ-NOH on red cells that more 
closely resemble G6PD deficient red cells (i.e. cells with reduced levels of GSH (Beutler, 
1978), rat red cells were treated with OEM to deplete GSH prior to exposure to hemolytic 
concentrations of MAQ-NOH. As seen in figure 3.5, GSH depletion markedly enhanced 
MAQ-NOH hemolytic activity as expected. However, the increase in toxicity was not 
accompanied by an increase in lipid peroxidation. Surprisingly, MAQ-NOH induced a 
concentration-dependent increase in membrane skeletal protein hemoglobin adducts in 
red cells absent of aSH. Collectively these data suggest that MAQ-NOH may mediate its 
hemolytic activity through more than one mechanism; one that involves lipid 
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peroxidation in red cells with notmal levels of GSH and protein oxidation in red, cells 
with decreased aSH levels, such as those seen in G6PD-deficient individuals. 
DEM-treated erythrocytes as a model ofG6PD deficiency 
Although DEM-treated red cells are more sensitive to oxidative injury, there are some 
differences between these cells and G6PD-deficient cells. First, GSH levels are known to 
be decreased in G6PD-deficient cells (Beutler, 1978), however in red cells exposed to 
DEM, aSH is essentially absent. Though DEM-treated red cells may represent G6PD 
cells following an oxidative stress. Secondly, DEM does not specifically react with GSH. 
Sulfhydryl groups on cellular proteins may also be blocked by DEM. In an effort to 
minimize this possibility, red cell GSH is titrated out with small aliquots of DEM. 
Furthermore, should any DEM side reactions be occurring in our experiments, this does 
not appear to effect the in vivo survival, levels of lipid peroxidation, or protein 
electrophoretic pattern of these red cells as indicated in control experiments. 
It is also important to note that a more specific method than DEM treatment does 
exits in which to model G6PD deficiency. This approach involves the use of steroids such 
as epiandrosterone to non-competitively inhibit G6PD (Marks and Banks, 1960). Our 
laboratory has previously employed this technique to demonstrate an enhanced sensitivity 
of G6PD inhibited rat red cells versus uninhibited cells to DDS-NOH (Grossman et aI., 
1995). The difference in sensitivity in these experiments was comparable to that seen by 
Degowin et al. in G6PD-deficient and normal individuals given dapsone (Degowin et al., 
1966). However, despite multiple attempts, we have been unable to successfully inhibit 
G6PD to the extent necessary to represent an A- G6PD deficient individual (>950/0 
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inhibition) since these studies. Efforts to elucidate the reason for this lack of response are 
being continued. 
Effect of MAQ-NOH on free radical formation in rat erythrocytes 
In light of the critical role of oxidative stress in drug-induced hemolytic anemia, 
additional experiments were conducted to detect and identify any free radicals generated 
in rat red cells exposed to hemolytic concentrations of MAQ-NOH. EPR analysis using 
the spin trap 2-ethoxycarbonyl-2-methyl-3,4-dihydro-2H-pyrrole-l-oxide (EMPO) 
revealed that in normal rat red cells, MAQ-NOH generated a hydroxyl radical adduct 
signal in a concentration-dependent manner. Surprisingly, this radical was continuously 
generated for up to 20 min despite that MAQ-NOH has a half-life of less than a minute in 
blood (Bolchoz et. aI., unpublished data). Furthermore, in conjunction with the above 
studies, red cells treated with DEM to deplete GSH prior to MAQ-NOH exposure were 
also examined by EPR. Interestingly, no radical adduct signal was detected under these 
conditions in rat red cells suggesting that MAQ-NOH-induced hydroxyl radical formation 
was GSH dependent. Of particular importance, these data raise the possibility that a third 
type of radical (i.e. compound-centered radical) may be initially generated in response to 
MAQ-NOH that reacts with GSH to ultimately give rise to a hydroxyl radical. This 
radical may also be more cytotoxic than the hydroxyl radical as MAQ-NOH hemolytic 
activity is known to be markedly enhanced in aSH-depleted red cells. Additional 
spectrophotometric analysis of MAQ-NOH treated red cells revealed the presence of 
ferrylhemoglobin, thereby confirming the presence of hydrogen peroxide and by 
inference superoxide in these cells. The role of ferryl heme species in MAQ-NOH 
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hemolytic activity remains to be determined. In addition, whether a compound-centered 
radical is produced in red cells in response to MAQ-NOH and its role in causing the 
intracellular lesions described above certainly warrants further investigation. 
Conclusion 
In trying to answer the question of which primaquine metabolite mediates its 
hemotoxic side effects, the first phase of this project was to determine if the known 
human primaquine metabolite 6-MAQ could be N-hydroxylated to MAQ-NOH .. Evidence 
is presented to show that MAQ-NOH is not only formed from 6-MAQ, but that it is 
directly hemotoxic. MAQ-NOH was further demonstrated to be hemolytic in vivo. 
Despite that this metabolite has ~he requisite properties to mediate parent compound 
hemolytic anemia, its relative contribution remains unclear. This is largely due to the 
possible contribution of the redox active phenolic metabolites to the toxicity. In this 
regard, preliminary studies in our laboratory have demonstrated that the phenolic 
metabolites of primaquine are also directly hemolytic (fig 5.1). In fact these metabolites 
appear to be markedly more potent than MAQ-NOH in normal rat erythrocytes. 
However, there exists no evidence to support that these metabolites are formed in 
humans. Furthermore, should these metabolites be produced in vivo, the possibility exists 
that they may never reach the circulation to mediate this toxicity due to their extreme 
chemical instability or further metabolism. In support, 2-aminophenol and 4-
aminophenol, the phenolic metabolites of anil~ne, although directly hemotoxic, were 
found to be rapidly eliminated by hepatic conjugation and not to contribute to the parent 
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Fig. 5.1. Survival of rat 51Cr-Iabeled erythrocytes in vivo after in vitro exposure to the 
phenolic metabolites of primaquine 5HQ, 5-hydroxy-6-methoxy-8-aminoquinoline, 
5HPQ, 5-hydroxyprimaquine, and 5,6DHPQ, 5,6-dihydroxyprimaquine. The red cells 
were incubated with the phenolic metabolites for 2 hr at 37°C; control cells were 
incubated with vehicle (PBSG) alone. The erythrocytes were then washed and 
administered i. v .. to isologous rats. To blood samples were taken 30 min after 
administration of the labeled cells. Data points are means + SD (n=4). 
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The second ............ U''''''' of this project focuses on mechanism of MAQ-NOH-induced 
particularly in comparison hemolytic arylhydroxylamines. 
studies MAQ-NOH was shown induce lipid peroxidation hemoglobin 
monomer with the plasma membrane under hemolytic conditions with 
on the membrane cytoskeletal proteins. This pattern of oxidative 
contrast to that seen previously with hemolytic such as 
""'"'>J""""""A_.AA et aI., 1992), phenylhydrazine (J andl et 1960), and divicine (McMillan et 
, 2001) particularly with respect to the lack hemoglobin adducts to the membrane 
cytoskeletal proteins. Of importance, these data question the relevance hemoglobin 
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one may speculate that 
leads to a conformational 
cell. 
may alter the lipid membrane in a manner 
in band 3 to trigger macrophage ingestion of 
In contrast to aSH-normal red cells, MAQ-NOH hemolytic activity was 
enhanced red cells previously depleted of GSH. The exacerbation of was 
accompanied by the formation of hemoglobin adducts to the membrane skeletal proteins 
with little effect on lipid peroxidation suggesting that both these mechanisms can 
__ , .... _~ __ macrophage recognition of damaged red cells. Moreover, should MAQ-NOH 
the metabolite responsible for primaquine-induced hemolytic _AA..,'''A.LL_. these data would 
provide for the first time a biochemical basis to explain the difference in sensitivity 
G6PD-deficient individuals' and G6PD-normal individuals primaquine and 
(Degowin ., 1966). It hoped that exploitation this unique 
future studies will ultimately provide some additional insight as to mechanism 
induced hemolytic anemia. 
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mechanism of MAQ-NOH-induced 
discovered that incubation of rat erythrocytes with 
exogenous aminothiol cysteamine, while to MAQ-NOH, does not protect the 
cells from MAQ-NOH-induced hemolytic injury seen previously witli DDS-NOH 
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To the contrary, 5 mM cysteamine significantly enhanced MAQ-NOH hemolytic 
activity when co-incubated rat erythrocytes. This was rather unexpected as 
GSH, is known di~ectly scavenge reactive free radicals 
sulfhydryl a reduced form thereby protecting the 
to maintain cellular 
cells from oxidati ve 
Additional experiments in which cysteamine was incubated with MAQ-NOH 
red cells previously depleted GSH revealed that cysteamine markedly 
exacerbated MAQ-NOH hemolytic damage in GSH-depleted cells 5 In . 
findings, our lab intends to examine the effects of cysteamine on MAQ-NOH-
induced alterations of the membrane lipids and proteins in both normal and GSH-
depleted rat red We also propose to use EPR to examine the radicals produced 
in rat red cells under .. A .. """-'''"'' various conditions as well as to continue our attempts 
any compound-centered radicals MAQ-NOH-treated erythrocytes. 
In summary, while it is difficult to speculate on the molecular mechanism MAQ-
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Fig. 5.2. The effect of cysteamine on the survival of rat 51Cr-labeled erythrocytes in vivo 
after in vitro exposure to (A) DDS-NOH (180 JlM) or (B) MAQ-NOH (450 JlM). The red 
cells were incubated with 5 mM cysteamine and either DDS-NOH or MAQ-NOH for 2 hr 
at 37°C; control cells were incubated with vehicle (FBSG) alone. The erythrocytes were 
then washed and administered i.v. to isologous rats. To blood samples were taken 30 min 
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Fig. 5.3. The effect of cysteamine on the survival of GSH-depleted 51 Cr-labeled rat 
erythrocytes in vivo after in vitro exposure to MAQ-NOH (250 ILM). Rat red cells were 
depleted of GSH (>90%) using DEM an.d incubated with either MAQ-NOH alone or 5 
mM cysteamine and MAQ-NOH for 2 hr at 37°C; control cells were incubated with 
vehicle (20 ILl DMSO) alone. The erythrocytes were then washed and administered i.v. to 
isologous rats. To blood samples were taken 30 min after administration of the labeled 
cells. Data points are means + SD (n=4). 
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